

Date: February 10, 2026

To,
The Department of Corporate Services,
BSE Limited,
25th Floor, P.J. Towers,
Dalal Street, Mumbai- 400001

Subject: Copies of Financial Results published in Newspapers

Ref: Regulation 30 & 47 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015

Scrip Code: 538734

Dear Sir/ Madam,

Please find enclosed herewith copies of Financial Results of the Company for the quarter and nine months ended December 31, 2025 as published in Business Standards (English); The Indian Express (English) and Loksatta (Marathi) today i.e. on February 10, 2026.

We request you to kindly take the above information on your record.

Thanking You.

Yours faithfully,

For Ceinsys Tech Limited

Pooja Karande
Company Secretary &
Compliance Officer
M. No. A54401

Enclosure: As above

Pharma Inc calls for easier regulatory prescription

Industry says approval delays, weak clinical trial infra holding back sector

ANALI SINGH
Mumbai, 10 February

ILLUSTRATION: ANIYA MOHANTY

India's leading pharmaceutical industry veterans have made a strong case for faster, simpler and more predictable regulations. They warned that delays in approvals, weak clinical trial infrastructure and poor domestic acceptance of Indian innovation are holding the sector back. This comes at a time when global peers—particularly China—are moving rapidly up the value chain.



Speaking at a panel discussion on the past and future of Indian pharma at the launch of the book 'Made in India—The Story of Desh Bandhu Gupta, Lupin and Indian Pharma', industry stalwarts, including Dilip Shanghvi, managing director of Sun Pharma, Yusuf Hamied, chairman of Cipla, G V Prasad, managing director of Dr Reddy's Laboratories and Vinita Gupta, chief executive officer (CEO) of Lupin, said India must urgently reform its regulatory ecosystem. This would help it transition from a generics-led model to higher-value innovation.

Eyeing a growth pill

- Sun Pharma MD Dilip Shanghvi said regulatory delays, especially in clinical trials, push early-stage studies abroad
- Dr Reddy's Laboratories MD G V Prasad said India underestimated China, which built innovation strength through faster approvals
- Cipla Chairman Yusuf Hamied said Indian innovation suffers from poor domestic acceptance
- Lupin CEO Vinita Gupta said India can innovate without multi-billion-dollar R&D by leveraging its patient pool, regulatory reform and incentives

The industry veterans highlighted how regulatory delays, especially in clinical trial approvals, are forcing Indian companies to conduct early-stage studies overseas. Shanghvi noted that Phase-I trials often get completed in countries such as Belgium or Australia before approvals come through in India, underscoring the need for smoother processes if the country wants to become an innovation hub.

He said the government's recent steps, including the production linked incentive-style PRIP scheme and plan to certify 1,000 clinical trial centres, signal intent, but execution will be key.

China emerged repeatedly as a point of comparison. Prasad said India has not done as well as China for years, seeing it mainly as a low-cost manufacturing base, while it quietly built a powerful innovation ecosystem.

He pointed to China's large reimbursed domestic market, faster regulatory clearances, rapid clinical development timelines and its success in attracting globally-trained biopharma leadership as critical advantages.

These factors, he said, have enabled Chinese firms to move beyond generics

into fast-follower and best-in-class innovation, a space that requires millions of dollars of investment per molecule and far higher risk tolerance.

The panel stressed that "fast follower" drugs should not be trivialised as incremental work.

Prasad described them as best-in-class innovations that demand expensive clinical trials, advanced medicinal chemistry and strong regulatory capabilities.

"This is a very different game from generics," he said, adding that innovation involves fewer but much larger bets compared with the multiple small bets, typical of generics.

Hamied traced India's pharma roots to policy choices that prioritised access over

monopoly, recalling the 1972 patent law changes that enabled domestic manufacturing of essential drugs.

While reiterating his support for science being rewarded through royalties, he argued against monopolistic pricing and said innovation in India continues to face a major hurdle: acceptability.

Indian doctors, he said, often remain sceptical of domestically-developed new drugs, asking why multinational companies have not launched them first.

Academia-industry collaboration also came under focus. Sharma said India has a cultural resistance to being "first in the world" and a reluctance to accept failure, both of which stifle innovation.

He stressed that applied research must ultimately find its way into industry and markets, and called for greater focus on areas such as biotransformation, formulation engineering and sustainable manufacturing. Here, India remains overly dependent on imports, particularly from China.

Gupta argued that India does not need to replicate the multi-billion-dollar research and development (R&D) spending of global pharma giants to innovate.

Instead, she said, companies can leverage India's large patient pool, improving regulatory pathways and government incentives to conduct faster development locally, establish proof of concept and then scale products globally.

She also highlighted opportunities in off-patent brands, specialty generics, biosimilars and novel formulations as lower-risk pathways to value creation.

While acknowledging that innovation requires significant capital and tolerance for failure, Shanghvi said Indian companies need a few visible success stories to build confidence across the industry.

Recent out-licensing deals, he said, show that Indian innovation can attract global interest if supported by the right ecosystem.

The overarching message from the panel was clear: without regulatory agility, better clinical infrastructure, stronger industry-academia links and a shift in mindset towards risk-taking and acceptance of failure, India risks ceding ground to faster-moving peers.

CKYC ID: One KEY for All Your KYC Needs



Unique 14-digit CKYC ID issued by CKYC Records Registry

HOW IT WORKS?

- Submit KYC details to your bank
- Bank uploads KYC details on Central KYC Records Registry
- Can be used across banks & financial institutions

Know your CKYC ID

- Missed call: 7799022129 or
- Online: www.kycindia.in

KEY BENEFITS

- 1 Open accounts easily with different banks/financial institutions
- 1 Simplifies KYC Update: KYC updated with one bank, gets updated in your all other banks/financial institutions through CKYC

Simple. Secure. Standardised.



Issued in public interest by भारतीय रिज़र्व बैंक RESERVE BANK OF INDIA www.rbi.org.in

APPOINTMENTS

Driving the delivery and growth of markets.

As a cornerstone of India's financial market infrastructure, MCX has been integral to India's economic growth, strengthening the markets through robust price discovery and effective risk management for the commodity ecosystem. Step into a leadership role that drives those markets into the future through a continued focus on innovation and governance.

LEADERSHIP OPENINGS

- EXECUTIVE DIRECTOR
Critical Operations (ED1)

Lead technology, cybersecurity, trading infrastructure and digital transformation at MCX, building future-ready market infrastructure at a national scale. Drive innovation in emerging technologies while safeguarding system resilience, reliability, integrity and regulatory compliance.

Apply at: ED1_MCX@sheffieldhaworth.com before 3 March 2026

- EXECUTIVE DIRECTOR
Regulatory, Compliance, Risk Management & Investor Grievances (ED2)

Provide enterprise-wide leadership across operational excellence, investigations, investor grievances, risk, regulatory compliance and governance. Engage closely with key stakeholders to uphold integrity, transparency and institutional credibility.

Apply at: ED2_MCX@sheffieldhaworth.com before 3 March 2026

- EXECUTIVE DIRECTOR
Business (ED3)

Lead business strategy and ecosystem relationships to increase diversity of participation and product development, liquidity enhancement and revenue diversification within a regulated market infrastructure, while maintaining strong brand positioning.

Apply at: ED3_MCX@sheffieldhaworth.com before 10 March 2026

LOCATION : MUMBAI

Multi Commodity Exchange of India Limited (MCX) is India's largest stock exchange in the commodity derivatives segment, recognised under the Securities Contracts (Regulation) Act, 1956, and regulated by SEBI as a Market Infrastructure Institution (MI).



MCX
METAL & ENERGY
Trade with Trust

Ceinsys Tech delivers strong revenue growth in Q3 FY26 with consistently improving EBITDA margins

Quarterly Revenue (INR Cr) and EBITDA Margins (%)

Quarter	Revenue (INR Cr)	YoY Growth (%)	EBITDA (INR Cr)	YoY Growth (%)	Profit (INR Cr)	YoY Growth (%)
Q1 FY25	73.8	17.92%	169.94	52%	38.87	118%
Q2 FY25	90.0	18.6%	39.91	88%	170	-
Q3 FY25	111.8	19.0%	-	-	-	-
Q4 FY25	142.4	18.80%	-	-	-	-
Q1 FY26	156.6	19.32%	-	-	-	-
Q2 FY26	163.5	21.79%	-	-	-	-
Q3 FY26	169.9	23.48%	-	-	-	-

- 27 Years of Legacy
- 200+ Customers
- Global Footprint Presence across US, Europe and India
- Geospatial Services
- Technology Solutions
- Automotive Engineering

Operational and other Highlights

Confirmed Order Book as on Dec. 31, 2025

₹999 Cr

Geospatial & Engineering Services revenue up by

76.5% YoY

Technology Solutions revenue up by

79.41% YoY

Major Milestones this Quarter

New order book during quarter

₹170 Cr

EXTRACT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2025 (in Rs. Cr)

Particulars	CONSOLIDATED					
	Quarter Ended		Nine Months Ended		Year Ended	
	31.12.2025	30.09.2025	31.12.2024	31.12.2024	31.03.2025	31.03.2025
Total Income from Operations (Net)	169.94	163.45	111.79	489.99	275.67	418.06
Net Profit/(Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	42.07	39.55	24.18	115.48	61.13	89.54
Net Profit/(Loss) for the period before tax (after Exceptional and/or Extraordinary items)	40.91	39.55	24.18	114.32	61.13	89.54
Net Profit/(Loss) for the period after tax (after Exceptional and/or Extraordinary items)	38.87	25.74	17.81	96.25	41.37	63.24
Total Comprehensive Income for the period (Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income (after tax))	38.81	26.17	18.46	96.36	41.99	63.60
Paid up Equity Share Capital (Equity Share of Rs. 10/- each)	17.84	17.84	17.44	17.84	17.44	17.44
Earnings Per Share (Face Value of Rs. 10/-)						
(1) Basic (*Not Annualised):	21.79*	14.47*	10.21*	54.41*	24.70*	37.37
(2) Diluted (*Not Annualised):	19.94*	12.94*	9.95*	48.76*	24.46*	35.27

1. The above is an extract of the detailed format of statement of Unaudited Consolidated Financial Results for the quarter and nine months ended December 31, 2025, filed with Stock Exchanges under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the said Financial Results are available on the Stock Exchange website at: www.bseindia.com and on the Company's website at: www.cstechai.com. The same could also be accessed by scanning the QR Code provided below.

2. The Unaudited Consolidated Financial Results of Ceinsys Tech Limited (the "Company") for the quarter and nine months ended December 31, 2025 (the "Statement") were reviewed by Audit Committee and approved by Board of Directors at their meeting held on February 9, 2026. The Statutory auditors of the Company have carried out a limited review of the above results for the quarter and nine months ended December 31, 2025.

Sd/-
Mr. Kaushik Khona
Managing Director, India Operations
DIN: 00026597

Place : Mumbai
Date : February 9, 2026
For and on behalf of Board of directors
Ceinsys Tech Limited

Registered Office : Ceinsys Tech Ltd, 10/S, IT Park, Nagpur - 440022, Maharashtra, India. CIN: L72300MH1998PLC14790
www.cstech.ai | contactus@csctech.ai | +91 712 6782800

Pharma Inc calls for easier regulatory prescription

Industry says approval delays, weak clinical trial infra holding back sector

ANALI SINGH
Mumbai, 10 February

ILLUSTRATION: ANIYA MOHANTY



India's leading pharmaceutical industry veterans have made a strong case for faster, simpler and more predictable regulations. They warned that delays in approvals, weak clinical trial infrastructure and poor domestic acceptance of Indian innovation are holding the sector back. This comes at a time when global peers—particularly China—are moving rapidly up the value chain.

Speaking at a panel discussion on the past and future of Indian pharma at the launch of the book 'Made in India—The Story of Desh Bandhu Gupta, Lupin and Indian Pharma', industry stalwarts, including Dilip Shanghvi, managing director of Sun Pharma, Yusuf Hamied, chairman of Cipla, G V Prasad, managing director of Dr Reddy's Laboratories and Vinita Gupta, chief executive officer (CEO) of Lupin, said India must urgently reform its regulatory ecosystem. This would help it transition from a generics-led model to higher-value innovation.

The industry veterans highlighted how regulatory delays, especially in clinical trial approvals, are forcing Indian companies to conduct early-stage studies overseas. Shanghvi noted that Phase-I trials often get completed in countries such as Belgium or Australia before approvals come through in India, underscoring the need for smoother processes if the country wants to become an innovation hub.

He said the government's recent steps, including the production linked incentive-style PLIP scheme and plans to certify 1,000 clinical trial centres, signal intent, but execution will be key.

China emerged repeatedly as a point of comparison. Prasad said India had underestimated China for years, seeing it mainly as a low-cost manufacturing base, while it quietly built a powerful innovation ecosystem.

He pointed to China's large reimbursed domestic market, faster regulatory clearances, rapid clinical development timelines and its success in attracting globally-trained biopharma leadership as critical advantages.

These factors, he said, have enabled Chinese firms to move beyond generics

Eyeing a growth pill

■ Sun Pharma MD Dilip Shanghvi said regulatory delays, especially in clinical trials, push early-stage studies abroad

■ Dr Reddy's Laboratories MD G V Prasad said India underestimated China, which built innovation strength through faster approvals

■ Cipla Chairman Yusuf Hamied said Indian innovation suffers from poor domestic acceptance

■ Lupin CEO Vinita Gupta said India can innovate without multi-billion-dollar R&D by leveraging its patient pool, regulatory reform and incentives

into fast-follower and best-in-class innovation, a space that requires millions of dollars of investment per molecule and far higher risk tolerance.

The panel stressed that "fast follower" drugs should not be trivialised as incremental work.

Prasad described them as best-in-class innovations that demand expensive clinical trials, advanced medicinal chemistry and strong regulatory capabilities.

"This is a very different game from generics," he said, adding that innovation involves fewer but much larger bets compared with the multiple small bets, typical of generics.

Hamied traced India's pharma roots to policy choices that prioritised access over

monopoly, recalling the 1972 patent law changes that enabled domestic manufacturing of essential drugs.

While reiterating his support for science being rewarded through royalties, he argued against monopolistic pricing and said innovation in India continues to face a major hurdle—acceptability.

Indian doctors, he said, often remain sceptical of domestically-developed new drugs, asking why multinational companies have not launched them first.

Academia-industry collaboration also came under focus.

Sharma said India has a cultural resistance to being "first in the world" and a reluctance to accept failure, both of which stifle innovation. He stressed that applied research must ultimately find its way into industry and markets, and called for greater focus on areas such as biotransformation, formulation engineering and sustainable manufacturing. Here, India remains overly dependent on imports, particularly from China.

Gupta argued that India does not need to replicate the multi-billion-dollar research and development (R&D) spending of global pharma giants to innovate. Instead, she said, companies can leverage India's large patient pool, improving regulatory pathways and government incentives to conduct faster development locally, establish proof of concept and then scale products globally.

She also highlighted opportunities in off-patent brands, speciality generics, biosimilars and novel formulations as lower-risk pathways to value creation.

While acknowledging that innovation requires significant capital and tolerance for failure, Shanghvi said Indian companies need a few visible success stories to build confidence across the industry.

Recent out-licensing deals, he said, show that Indian innovation can attract global interest if supported by the right ecosystem.


The overarching message from the panel was clear: without regulatory agility, better clinical infrastructure, stronger industry-academia links and a shift in mindset towards risk-taking and acceptance of failure, India risks ceding ground to faster-moving peers.

Curators of the unique.

Exclusively Marketed By

1 of 1

India | Sotheby's
INTERNATIONAL REALTY



Villa in Moira, North Goa
For Sale

Plot size = 4,200 sqm (≈ 1 acre) | Area ≈ 1,045 sqm (≈ 11,290 sq. ft.)
6 bedrooms

To schedule a viewing, contact:
Tushar Ahuja | +91 92899 68270
tushar.ahuja@sothebysrealty.in



Scan to enquire

26,100 Sales Associates | 1,100 Offices | 84 Countries & Territories

India Sotheby's International Realty is a trademark of Realpro Realty Solutions Pvt. Ltd. No representations and warranties are made with respect to the completeness or accuracy of information concerning the property's size, amenities, facilities etc., which are published herein in good faith. The offerings are subject to errors, omissions, changes, including price, or withdrawal without notice. You are requested to get in touch with one of our agents via the contact details above. Each Office is Independently Owned & Operated.

APPOINTMENTS

Driving the delivery and growth of markets.

As a cornerstone of India's financial market infrastructure, MCX has been integral to India's economic growth, strengthening the markets through robust price discovery and effective risk management for the commodity ecosystem. Step into a leadership role that drives those markets into the future through a continued focus on innovation and governance.

LEADERSHIP OPENINGS

EXECUTIVE DIRECTOR Critical Operations (ED1)

Lead technology, cybersecurity, trading infrastructure and digital transformation at MCX, building future-ready market infrastructure at a national scale. Drive innovation in emerging technologies while safeguarding system resilience, reliability, integrity and regulatory compliance.

Apply at: ED1_MCX@sheffieldhaworth.com before 3 March 2026

EXECUTIVE DIRECTOR Regulatory, Compliance, Risk Management & Investor Grievances (ED2)

Provide enterprise-wide leadership across operational excellence, investigations, investor grievances, risk, regulatory compliance and governance. Engage closely with key stakeholders to uphold integrity, transparency and institutional credibility.

Apply at: ED2_MCX@sheffieldhaworth.com before 3 March 2026

EXECUTIVE DIRECTOR Business (ED3)

Lead business strategy and ecosystem relationships to increase diversity of participation and product development, liquidity enhancement and revenue diversification within a regulated market infrastructure, while maintaining strong brand positioning.


Apply at: ED3_MCX@sheffieldhaworth.com before 10 March 2026

LOCATION : MUMBAI

Multi Commodity Exchange of India Limited (MCX) is India's largest stock exchange in the commodity derivatives segment, recognised under the Securities Contracts (Regulation) Act, 1956, and regulated by SEBI as a Market Infrastructure Institution (MII).



Ceinsys Tech delivers strong revenue growth in Q3 FY26 with consistently improving EBITDA margins



For Nine months ended December 31, 2025

Operational and other Highlights	Confirmed Order Book as on Dec. 31, 2025: ₹999 Cr	Geospatial & Engineering Services revenue up by 76.5% YoY	Technology Solutions revenue up by 79.41% YoY	Major Milestones this Quarter: New order book during quarter ₹170 Cr
----------------------------------	---	---	---	--

EXTRACT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2025

Particulars	CONSOLIDATED					
	Quarter Ended		Nine Months Ended		Year Ended	
	31.12.2025	30.09.2025	31.12.2024	31.12.2025	31.12.2024	31.03.2025
Total Income from Operations (Net)	169.94	163.45	111.79	489.99	275.67	418.06
Net Profit/(Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	42.07	39.55	24.18	115.48	61.13	89.54
Net Profit/(Loss) for the period before tax (after Exceptional and/or Extraordinary items)	40.91	39.55	24.18	114.32	61.13	89.54
Net Profit/(Loss) for the period after tax (after Exceptional and/or Extraordinary items)	38.87	25.74	17.81	96.25	41.37	63.24
Total Comprehensive Income for the period (Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income (after tax))	38.81	26.17	18.46	96.36	41.99	63.60
Paid up Equity Share Capital (Equity Share of Rs. 10/- each)	17.84	17.84	17.44	17.84	17.44	17.44
Earnings Per Share (Face Value of Rs. 10/-)						
(1) Basic (*Not Annualised)	21.79*	14.47*	10.21*	54.41*	24.70*	37.37
(2) Diluted (*Not Annualised)	19.94*	12.94*	9.95*	48.76*	24.46*	35.27

1. The above is an extract of the detailed form of statement of Unaudited Consolidated Financial Results for the quarter and nine months ended on December 31, 2025, filed with Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full form of the said Financial Results are available on the Stock Exchange website at: www.bseindia.com and on the Company's website at: www.ceinsystech.com. The same could also be accessed by scanning the QR Code provided below.

2. The Unaudited Consolidated Financial Results of Ceinsys Tech Limited (the "Company") for the quarter and nine months ended on December 31, 2025 (the "Statement") were reviewed by Audit Committee and approved by Board of Directors at their meeting held on February 9, 2026. The statutory auditors of the Company has carried out a limited review of the above results for the quarter and nine months ended December 31, 2025.

Sd/-
Mr. Kaushik Khona
Managing Director, India Operations
DIN: 00026597

Place : Mumbai
Date : February 9, 2026
For and on behalf of Board of directors
Ceinsys Tech Limited

Registered Office : Ceinsys Tech Ltd, 10/5, IT Park, Nagpur - 440022, Maharashtra, India. | CIN: L72300MH1998PLC114790
www.cstech.ai | contactus@csstech.ai | +91 712 6782800

Pharma Inc calls for easier regulatory prescription

Industry says approval delays, weak clinical trial infra holding back sector

ANALI SINGH
Mumbai, 10 February

ILLUSTRATION: ANIYA MOHANTY

India's leading pharmaceutical industry veterans have made a strong case for faster, simpler and more predictable regulations. They warned that delays in approvals, weak clinical trial infrastructure and poor domestic acceptance of Indian innovation are holding the sector back. This comes at a time when global peers—particularly China—are moving rapidly up the value chain.



Speaking at a panel discussion on the past and future of Indian pharma at the launch of the book 'Made in India—The Story of Desh Bandhu Gupta, Lupin and Indian Pharma', industry stalwarts, including Dilip Shanghvi, managing director of Sun Pharma, Yusuf Hamied, chairman of Cipla, G V Prasad, managing director of Dr Reddy's Laboratories and Vinita Gupta, chief executive officer (CEO) of Lupin, said India must urgently reform its regulatory ecosystem. This would help it transition from a generics-led model to higher-value innovation.

Eyeing a growth pill

- Sun Pharma MD Dilip Shanghvi said regulatory delays, especially in clinical trials, push early-stage studies abroad
- Dr Reddy's Laboratories MD G V Prasad said India underestimated China, which built innovation strength through faster approvals
- Cipla Chairman Yusuf Hamied said Indian innovation suffers from poor domestic acceptance
- Lupin CEO Vinita Gupta said India can innovate without multi-billion-dollar R&D by leveraging its patient pool, regulatory reform and incentives

The industry veterans highlighted how regulatory delays, especially in clinical trial approvals, are forcing Indian companies to conduct early-stage studies overseas.

Shanghvi noted that Phase-I trials often get completed in countries such as Belgium or Australia before approvals come through in India, underscoring the need for smoother processes if the country wants to become an innovation hub.

He said the government's recent steps, including the production linked incentive-style PRIP scheme and plan to certify 1,000 clinical trial centres, signal intent, but execution will be key.

China emerged repeatedly as a point of comparison. Prasad said India has underestimated China for years, seeing it mainly as a low-cost manufacturing base, while it quietly built a powerful innovation ecosystem.

He pointed to China's large reimbursed domestic market, faster regulatory clearances, rapid clinical development timelines and its success in attracting globally-trained biopharma leadership as critical advantages.

These factors, he said, have enabled Chinese firms to move beyond generics

into fast-follower and best-in-class innovation, a space that requires millions of dollars of investment per molecule and far higher risk tolerance.

"The panel stressed that 'fast follower' drugs should not be trivialised as incremental work.

Prasad described them as best-in-class innovations that demand expensive clinical trials, advanced medicinal chemistry and strong regulatory capabilities.

"This is a very different game from generics," he said, adding that innovation involves fewer but much larger bets compared with the multiple small bets, typical of generics.

Hamied traced India's pharma roots to policy choices that prioritised access over

monopoly, recalling the 1972 patent law changes that enabled domestic manufacturing of essential drugs.

While reiterating his support for science being rewarded through royalties, he argued against monopolistic pricing and said innovation in India continues to face a major hurdle: acceptability.

Indian doctors, he said, often remain sceptical of domestically-developed new drugs, asking why multinational companies have not launched them first.

Academia-industry collaboration also came under focus.

Sharma said India has a cultural resistance to being "first in the world" and a reluctance to accept failure, both of which stifle innovation.

He stressed that applied research must ultimately find its way into industry and markets, and called for greater focus on areas such as biotransformation, formulation engineering and sustainable manufacturing. Here, India remains overly dependent on imports, particularly from China.

Gupta argued that India does not need to replicate the multi-billion-dollar research and development (R&D) spending of global pharma giants to innovate.

Instead, she said, companies can leverage India's large patient pool, improving regulatory pathways and government incentives to conduct faster development locally, establish proof of concept and then scale products globally.

She also highlighted opportunities in off-patent brands, speciality generics, biosimilars and novel formulations as lower-risk pathways to value creation.

While acknowledging that innovation requires significant capital and tolerance for failure, Shanghvi said Indian companies need a few visible success stories to build confidence across the industry.

Recent out-licensing deals, he said, show that Indian innovation can attract global interest if supported by the right ecosystem.

The overarching message from the panel was clear: without regulatory agility, better clinical infrastructure, stronger industry-academia links and a shift in mindset towards risk-taking and acceptance of failure, India risks ceding ground to faster-moving peers.

CKYC ID: One KEY for All Your KYC Needs



Unique 14-digit CKYC ID issued by CKYC Records Registry

HOW IT WORKS?

- Submit KYC details to your bank
- Bank uploads KYC details on Central KYC Records Registry
- Can be used across banks & financial institutions

Know your CKYC ID

- Missed call: 7799021219 or
- Online: www.kycindia.in

KEY BENEFITS

- 1 Open accounts easily with different banks/financial institutions
- 1 Simplifies KYC Update: KYC updated with one bank, gets updated in your all other banks/financial institutions through CKYC

Simple. Secure. Standardised.



Issued in public interest by भारतीय रिज़र्व बैंक RESERVE BANK OF INDIA www.rbi.org.in

APPOINTMENTS

Driving the delivery and growth of markets.

As a cornerstone of India's financial market infrastructure, MCX has been integral to India's economic growth, strengthening the markets through robust price discovery and effective risk management for the commodity ecosystem. Step into a leadership role that drives those markets into the future through a continued focus on innovation and governance.

LEADERSHIP OPENINGS

- EXECUTIVE DIRECTOR
Critical Operations (ED1)

Lead technology, cybersecurity, trading infrastructure and digital transformation at MCX, building future-ready market infrastructure at a national scale. Drive innovation in emerging technologies while safeguarding system resilience, reliability, integrity and regulatory compliance.

Apply at: ED1_MCX@sheffieldhaworth.com before 3 March 2026

- EXECUTIVE DIRECTOR
Regulatory, Compliance, Risk Management & Investor Grievances (ED2)

Provide enterprise-wide leadership across operational excellence, investigations, investor grievances, risk, regulatory compliance and governance. Engage closely with key stakeholders to uphold integrity, transparency and institutional credibility.

Apply at: ED2_MCX@sheffieldhaworth.com before 3 March 2026

- EXECUTIVE DIRECTOR
Business (ED3)

Lead business strategy and ecosystem relationships to increase diversity of participation and product development, liquidity enhancement and revenue diversification within a regulated market infrastructure, while maintaining strong brand positioning.

Apply at: ED3_MCX@sheffieldhaworth.com before 10 March 2026

LOCATION : MUMBAI

Multi Commodity Exchange of India Limited (MCX) is India's largest stock exchange in the commodity derivatives segment, recognised under the Securities Contracts (Regulation) Act, 1956, and regulated by SEBI as a Market Infrastructure Institution (MI).



MCX
METAL & ENERGY
Trade with Trust

Ceinsys Tech delivers strong revenue growth in Q3 FY26 with consistently improving EBITDA margins

Quarterly Revenue (INR Cr) and EBITDA Margins (%)

Quarter	Revenue (INR Cr)	YoY Growth (%)	EBITDA (INR Cr)	YoY Growth (%)	EBITDA Margin (%)	YoY Growth (%)
Q1 FY25	73.8	17.92%	169.94	52%	19.32%	88%
Q2 FY25	90.0	18.6%	199.9	88%	21.79%	88%
Q3 FY25	111.8	19.0%	399.9	88%	23.48%	118%
Q4 FY25	142.4	18.80%	-	-	-	-
Q1 FY26	156.6	19.32%	-	-	-	-
Q2 FY26	163.5	21.79%	-	-	-	-
Q3 FY26	169.9	23.48%	-	-	-	-

- 27 Years of Legacy
- 200+ Customers
- Global Footprint Presence across US, Europe and India
- Geospatial Services
- Technology Solutions
- Automotive Engineering

Operational and other Highlights

Confirmed Order Book as on Dec. 31, 2025

₹999 Cr

Geospatial & Engineering Services revenue up by

76.5% YoY

Technology Solutions revenue up by

79.41% YoY

Major Milestones this Quarter

New order book during quarter

₹170 Cr

EXTRACT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2025 (in Rs. Cr)

Particulars	CONSOLIDATED					
	Quarter Ended		Nine Months Ended		Year Ended	
	31.12.2025	30.09.2025	31.12.2024	30.09.2024	31.03.2025	
Total Income from Operations (Net)	169.94	163.45	111.79	489.99	275.67	418.06
Net Profit/(Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	42.07	39.55	24.18	115.48	61.13	89.54
Net Profit/(Loss) for the period before tax (after Exceptional and/or Extraordinary items)	40.91	39.55	24.18	114.32	61.13	89.54
Net Profit/(Loss) for the period after tax (after Exceptional and/or Extraordinary items)	38.87	25.74	17.81	96.25	41.37	63.24
Total Comprehensive Income for the period (Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income (after tax))	38.81	26.17	18.46	96.36	41.99	63.60
Paid up Equity Share Capital (Equity Share of Rs. 10/- each)	17.84	17.84	17.44	17.84	17.44	17.44
Earnings Per Share (Face Value of Rs. 10/-)						
(1) Basic (*Not Annualised):	21.79*	14.47*	10.21*	54.41*	24.70*	37.37
(2) Diluted (**Not Annualised):	19.94*	12.94*	9.95*	48.76*	24.46*	35.27

1. The above is an extract of the detailed format of statement of Unaudited Consolidated Financial Results for the quarter and nine months ended on December 31, 2025, filed with Stock Exchanges under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full form of the said Financial Results are available on the Stock Exchange website at: www.bseindia.com and on the Company's website at: www.ceinsys.com. The same could also be accessed by scanning the QR Code provided below.

2. The Unaudited Consolidated Financial Results of Ceinsys Tech Limited (the "Company") for the quarter and nine months ended on December 31, 2025 (the "Statement") were reviewed by Audit Committee and approved by Board of Directors at their meeting held on February 9, 2026. The Statutory auditors of the Company have carried out a limited review of the above results for the quarter and nine months ended December 31, 2025.

Sd/-
Mr. Kaushik Khona
Managing Director, India Operations
DIN: 00026597

Place : Mumbai
Date : February 9, 2026
For and on behalf of Board of directors
Ceinsys Tech Limited

Registered Office : Ceinsys Tech Ltd, 10/5, IT Park, Nagpur - 440022, Maharashtra, India. CIN: L7300MH1998PLC14790
www.ceinsys.com | contact@ceinsys.com | 020-26738960

Pharma Inc calls for easier regulatory prescription

Industry says approval delays, weak clinical trial infra holding back sector

ANALI SINGH
Mumbai, 10 February

ILLUSTRATION: ANIYA MOHANTY

India's leading pharmaceutical industry veterans have made a strong case for faster, simpler and more predictable regulation. They warned that delays in approvals, weak clinical trial infrastructure and poor domestic acceptance of Indian innovation are holding the sector back. This comes at a time when global peers—particularly China—are moving rapidly up the value chain.



Speaking at a panel discussion on the past and future of Indian pharma at the launch of the book 'Made in India—The Story of Desh Bandhu Gupta, Lupin and Indian Pharma', industry stalwarts, including Dilip Shanghvi, managing director of Sun Pharma, Yusuf Hamied, chairman of Cipla, G V Prasad, managing director of Dr Reddy's Laboratories and Vinita Gupta, chief executive officer (CEO) of Lupin, said India must urgently reform its regulatory ecosystem. This would help it transition from a generics-led model to higher-value innovation.

Eyeing a growth pill

- Sun Pharma MD Dilip Shanghvi said regulatory delays, especially in clinical trials, push early-stage studies abroad
- Dr Reddy's Laboratories MD G V Prasad said India underestimated China, which built innovation strength through faster approvals
- Cipla Chairman Yusuf Hamied said Indian innovation suffers from poor domestic acceptance
- Lupin CEO Vinita Gupta said India can innovate without multi-billion-dollar R&D by leveraging its patient pool, regulatory reform and incentives

The industry veterans highlighted how regulatory delays, especially in clinical trial approvals, are forcing Indian companies to conduct early-stage studies overseas. Shanghvi noted that Phase-I trials often get completed in countries such as Belgium or Australia before approvals come through in India, underscoring the need for smoother processes if the country wants to become an innovation hub.

He said the government's recent steps, including the production linked incentive-style PRIP scheme and plan to certify 1,000 clinical trial centres, signal intent, but execution will be key.

China emerged repeatedly as a point of comparison. Prasad said India has underestimated China for years, seeing it mainly as a low-cost manufacturing base, while it quietly built a powerful innovation ecosystem.

The panel stressed that "fast follower" drugs should not be trivialised as incremental work. "This is a very different game from generics," he said, adding that innovation involves fewer but much larger bets compared with the multiple small bets, typical of generics.

These factors, he said, have enabled Chinese firms to move beyond generic

into fast-follower and best-in-class innovation, a space that requires millions of dollars of investment per molecule and far higher risk tolerance.

Hamied traced India's pharma roots to policy choices that prioritised access over

monopoly, recalling the 1972 patent law changes that enabled domestic manufacturing of essential drugs.

While reiterating his support for science being rewarded through royalties, he argued against monopolistic pricing and said innovation in India continues to face a major hurdle—acceptability.

Indian doctors, he said, often remain sceptical of domestically-developed new drugs, asking why multinational companies have not launched them first.

Academia-industry collaboration also came under focus. Sharma said India has a cultural resistance to being "first in the world" and a reluctance to accept failure, both of which stifle innovation.

He stressed that applied research must ultimately find its way into industry and markets, and called for greater focus on areas such as biotransformation, formulation engineering and sustainable manufacturing. Here, India remains overly dependent on imports, particularly from China.

Gupta argued that India does not need to replicate the multi-billion-dollar research and development (R&D) spending of global pharma giants to innovate.

Instead, she said, companies can leverage India's large patient pool, improving regulatory pathways and government incentives to conduct faster development locally, establish proof of concept and then scale products globally.

She also highlighted opportunities in off-patent brands, speciality generics, biosimilars and novel formulations as lower-risk pathways to value creation.

While acknowledging that innovation requires significant capital and tolerance for failure, Shanghvi said Indian companies need a few visible success stories to build confidence across the industry.

Recent out-licensing deals, he said, show that Indian innovation can attract global interest if supported by the right ecosystem.

The overarching message from the panel was clear: without regulatory agility, better clinical infrastructure, stronger industry-academia links and a shift in mindset towards risk-taking and acceptance of failure, India risks ceding ground to faster-moving peers.

CKYC ID: One KEY for All Your KYC Needs



Unique 14-digit CKYC ID issued by CKYC Records Registry

HOW IT WORKS?

- Submit KYC details to your bank
- Bank uploads KYC details on Central KYC Records Registry
- Can be used across banks & financial institutions

Know your CKYC ID

- Missed call: 7799022129 or
- Online: www.kycindia.in

KEY BENEFITS

- 1 Open accounts easily with different banks/financial institutions
- 1 Simplifies KYC Update: KYC updated with one bank, gets updated in your all other banks/financial institutions through CKYC

Simple. Secure. Standardised.



Issued in public interest by भारतीय रिज़र्व बैंक RESERVE BANK OF INDIA www.rbi.org.in

APPOINTMENTS

Driving the delivery and growth of markets.

As a cornerstone of India's financial market infrastructure, MCX has been integral to India's economic growth, strengthening the markets through robust price discovery and effective risk management for the commodity ecosystem. Step into a leadership role that drives those markets into the future through a continued focus on innovation and governance.

LEADERSHIP OPENINGS

EXECUTIVE DIRECTOR Critical Operations (ED1)

Lead technology, cybersecurity, trading infrastructure and digital transformation at MCX, building future-ready market infrastructure at a national scale. Drive innovation in emerging technologies while safeguarding system resilience, reliability, integrity and regulatory compliance.

Apply at: ED1_MCX@sheffieldhaworth.com before 3 March 2026

EXECUTIVE DIRECTOR Regulatory, Compliance, Risk Management & Investor Grievances (ED2)

Provide enterprise-wide leadership across operational excellence, investigations, investor grievances, risk, regulatory compliance and governance. Engage closely with key stakeholders to uphold integrity, transparency and institutional credibility.

Apply at: ED2_MCX@sheffieldhaworth.com before 3 March 2026

EXECUTIVE DIRECTOR Business (ED3)

Lead business strategy and ecosystem relationships to increase diversity of participation and product development, liquidity enhancement and revenue diversification within a regulated market infrastructure, while maintaining strong brand positioning.

Apply at: ED3_MCX@sheffieldhaworth.com before 10 March 2026

LOCATION : MUMBAI

Multi Commodity Exchange of India Limited (MCX) is India's largest stock exchange in the commodity derivatives segment, recognised under the Securities Contracts (Regulation) Act, 1956, and regulated by SEBI as a Market Infrastructure Institution (MI).



MCX
METAL & ENERGY
Trade with Trust

Ceinsys Tech delivers strong revenue growth in Q3 FY26 with consistently improving EBITDA margins

Quarterly Revenue (INR Cr) and EBITDA Margins (%)

Quarter	Revenue (INR Cr)	YoY Growth (%)	EBITDA (INR Cr)	YoY Growth (%)	Profit (INR Cr)	YoY Growth (%)
Q1 FY25	73.8	17.92%	169.94	52%	169.94	52%
Q2 FY25	90.0	18.6%	199.9	88%	199.9	88%
Q3 FY25	111.8	19.0%	399.9	88%	399.9	88%
Q4 FY25	142.4	18.80%	-	-	-	-
Q1 FY26	156.6	19.32%	-	-	-	-
Q2 FY26	163.5	21.79%	-	-	-	-
Q3 FY26	169.9	23.48%	-	-	-	-

27 Years of Legacy

200+ Customers

Global Footprint
Presence across US, Europe and India

Operational and other Highlights

Confirmed Order Book as on Dec. 31, 2025

₹999 Cr

Geospatial & Engineering Services revenue up by

76.5% YoY

Technology Solutions revenue up by

79.41% YoY

Major Milestones this Quarter

New order book during quarter

₹170 Cr

EXTRACT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2025

Particulars	CONSOLIDATED					
	Quarter Ended		Nine Months Ended		Year Ended	
	31.12.2025	30.09.2025	31.12.2024	31.12.2024	31.03.2025	
Total Income from Operations (Net)	169.94	163.45	111.79	489.99	275.67	418.06
Net Profit/(Loss) for the period (before Tax, Exceptional and/or Extraordinary Items)	42.07	39.55	24.18	115.48	61.13	89.54
Net Profit/(Loss) for the period before tax (after Exceptional and/or Extraordinary Items)	40.91	39.55	24.18	114.32	61.13	89.54
Net Profit/(Loss) for the period after tax (after Exceptional and/or Extraordinary Items)	38.87	25.74	17.81	96.25	41.37	63.24
Total Comprehensive Income for the period (Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income (after tax))	38.81	26.17	18.46	96.36	41.99	63.60
Paid up Equity Share Capital (Equity Share of Rs. 10/- each)	17.84	17.84	17.44	17.84	17.44	17.44
Earnings Per Share (Face Value of Rs. 10/-)						
(1) Basic (*Not Annualised):	21.79*	14.47*	10.21*	54.41*	24.70*	37.37
(2) Diluted (**Not Annualised):	19.94*	12.94*	9.95*	48.76*	24.46*	35.27

1. The above is an extract of the detailed format of statement of Unaudited Consolidated Financial Results for the quarter and nine months ended on December 31, 2025, filed with Stock Exchanges under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the said Financial Results are available on the Stock Exchange website at: www.bseindia.com and on the Company's website at: www.cstechnai.com. The same could also be accessed by scanning the QR Code provided below.

2. The Unaudited Consolidated Financial Results of Ceinsys Tech Limited (the "Company") for the quarter and nine months ended on December 31, 2025 (the "Statement") were reviewed by Audit Committee and approved by Board of Directors at their meeting held on February 9, 2026. The Statutory auditors of the Company have carried out a limited review of the above results for the quarter and nine months ended December 31, 2025.

Sd/-
Mr. Kaushik Khona
Managing Director, India Operations
DIN: 00026597

Place : Mumbai Date : February 9, 2026 For and on behalf of Board of directors
Ceinsys Tech Limited

Registered Office : Ceinsys Tech Ltd, 10/S, IT Park, Nagpur - 440022, Maharashtra, India. CIN: L72300MH1998PL14790
www.cstech.ai contactus@csctech.ai +91 712 6782800

Pharma Inc calls for easier regulatory prescription

Industry says approval delays, weak clinical trial infra holding back sector

ANALI SINGH
Mumbai, 10 February

ILLUSTRATION: ANIYA MOHANTY

India's leading pharmaceutical industry veterans have made a strong case for faster, simpler and more predictable regulation. They warned that delays in approvals, weak clinical trial infrastructure and poor domestic acceptance of Indian innovation are holding the sector back. This comes at a time when global peers—particularly China—are moving rapidly up the value chain.



Speaking at a panel discussion on the past and future of Indian pharma at the launch of the book 'Made in India—The Story of Desh Bandhu Gupta, Lupin and Indian Pharma', industry stalwarts, including Dilip Shanghvi, managing director of Sun Pharma, Yusuf Hamied, chairman of Cipla, G V Prasad, managing director of Dr Reddy's Laboratories and Vinita Gupta, chief executive officer (CEO) of Lupin, said India must urgently reform its regulatory ecosystem. This would help it transition from a generics-led model to higher-value innovation.

Eyeing a growth pill

- Sun Pharma MD Dilip Shanghvi said regulatory delays, especially in clinical trials, push early-stage studies abroad
- Dr Reddy's Laboratories MD G V Prasad said India underestimated China, which built innovation strength through faster approvals
- Cipla Chairman Yusuf Hamied said Indian innovation suffers from poor domestic acceptance
- Lupin CEO Vinita Gupta said India can innovate without multi-billion-dollar R&D by leveraging its patient pool, regulatory reform and incentives

The industry veterans highlighted how regulatory delays, especially in clinical trial approvals, are forcing Indian companies to conduct early-stage studies overseas.

Shanghvi noted that Phase-I trials often get completed in countries such as Belgium or Australia before approvals come through in India, underscoring the need for smoother processes if the country wants to become an innovation hub.

He said the government's recent steps, including the production linked incentive-style PRIP scheme and plan to certify 1,000 clinical trial centres, signal intent, but execution will be key.

China emerged repeatedly as a point of comparison. Prasad said India has underestimated China for years, seeing it mainly as a low-cost manufacturing base, while it quietly built a powerful innovation ecosystem.

He pointed to China's large reimbursed domestic market, faster regulatory clearance, rapid clinical development timelines and its success in attracting globally-trained biopharma leadership as critical advantages.

These factors, he said, have enabled Chinese firms to move beyond generics

into fast-follower and best-in-class innovation, a space that requires millions of dollars of investment per molecule and far higher risk tolerance.

The panel stressed that "fast follower" drugs should not be trivialised as incremental work.

Prasad described them as best-in-class innovations that demand expensive clinical trials, advanced medicinal chemistry and strong regulatory capabilities.

"This is a very different game from generics," he said, adding that innovation involves fewer but much larger bets compared with the multiple small bets, typical of generics.

Hamied traced India's pharma roots to policy choices that prioritised access over

monopoly, recalling the 1972 patent law changes that enabled domestic manufacturing of essential drugs.

While reiterating his support for science being rewarded through royalties, he argued against monopolistic pricing and said innovation in India continues to face a major hurdle: acceptability.

Indian doctors, he said, often remain sceptical of domestically-developed new drugs, asking why multinational companies have not launched them first.

Academia-industry collaboration also came under focus.

Sharma said India has a cultural resistance to being "first in the world" and a reluctance to accept failure, both of which stifle innovation.

He stressed that applied research must ultimately find its way into industry and markets, and called for greater focus on areas such as biotransformation, formulation engineering and sustainable manufacturing. Here, India remains overly dependent on imports, particularly from China.

Gupta argued that India does not need to replicate the multi-billion-dollar research and development (R&D) spending of global pharma giants to innovate.

Instead, she said, companies can leverage India's large patient pool, improving regulatory pathways and government incentives to conduct faster development locally, establish proof of concept and then scale products globally.

She also highlighted opportunities in off-patent brands, specialty generics, biosimilars and novel formulations as lower-risk pathways to value creation.

While acknowledging that innovation requires significant capital and tolerance for failure, Shanghvi said Indian companies need a few visible success stories to build confidence across the industry.

Recent out-licensing deals, he said, show that Indian innovation can attract global interest if supported by the right ecosystem.

The overarching message from the panel was clear: without regulatory agility, better clinical infrastructure, stronger industry-academia links and a shift in mindset towards risk-taking and acceptance of failure, India risks ceding ground to faster-moving peers.

CKYC ID: One KEY for All Your KYC Needs



Unique 14-digit CKYC ID issued by CKYC Records Registry

HOW IT WORKS?

- Submit KYC details to your bank
- Bank uploads KYC details on Central KYC Records Registry
- Can be used across banks & financial institutions

Know your CKYC ID

- Missed call: 7799022129 or
- Online: www.kycindia.in

KEY BENEFITS

- 1 Open accounts easily with different banks/financial institutions
- 1 Simplifies KYC Update: KYC updated with one bank, gets updated in your all other banks/financial institutions through CKYC

Simple. Secure. Standardised.



Issued in public interest by भारतीय रिज़र्व बैंक RESERVE BANK OF INDIA www.rbi.org.in

APPOINTMENTS

Driving the delivery and growth of markets.

As a cornerstone of India's financial market infrastructure, MCX has been integral to India's economic growth, strengthening the markets through robust price discovery and effective risk management for the commodity ecosystem. Step into a leadership role that drives those markets into the future through a continued focus on innovation and governance.

LEADERSHIP OPENINGS

- EXECUTIVE DIRECTOR
Critical Operations (ED1)

Lead technology, cybersecurity, trading infrastructure and digital transformation at MCX, building future-ready market infrastructure at a national scale. Drive innovation in emerging technologies while safeguarding system resilience, reliability, integrity and regulatory compliance.

Apply at: ED1_MCX@sheffieldhaworth.com before 3 March 2026

- EXECUTIVE DIRECTOR
Regulatory, Compliance, Risk Management & Investor Grievances (ED2)

Provide enterprise-wide leadership across operational excellence, investigations, investor grievances, risk, regulatory compliance and governance. Engage closely with key stakeholders to uphold integrity, transparency and institutional credibility.

Apply at: ED2_MCX@sheffieldhaworth.com before 3 March 2026

- EXECUTIVE DIRECTOR
Business (ED3)

Lead business strategy and ecosystem relationships to increase diversity of participation and product development, liquidity enhancement and revenue diversification within a regulated market infrastructure, while maintaining strong brand positioning.

Apply at: ED3_MCX@sheffieldhaworth.com before 10 March 2026

LOCATION : MUMBAI


Multi Commodity Exchange of India Limited (MCX) is India's largest stock exchange in the commodity derivatives segment, recognised under the Securities Contracts (Regulation) Act, 1956, and regulated by SEBI as a Market Infrastructure Institution (MI).



MCX
METAL & ENERGY
Trade with Trust

CS TECH AI Enabling Possibilities

Ceinsys Tech delivers strong revenue growth in Q3 FY26 with consistently improving EBITDA margins



- 27 Years of Legacy
- 200+ Customers
- Global Footprint Presence across US, Europe and India
- Geospatial Services
- Technology Solutions
- Automotive Engineering

Operational and other Highlights: Confirmed Order Book as on Dec. 31, 2025: ₹999 Cr; Geospatial & Engineering Services revenue up by 76.5% YoY; Technology Solutions revenue up by 79.41% YoY.

Major Milestones this Quarter: New order book during quarter: ₹170 Cr; Strategic Partnership with Tech4B & Anterisk (Singapore) - Renewed global presence of Enterprise Geospatial Programs.

EXTRACT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2025

Particulars	CONSOLIDATED					
	Quarter Ended		Nine Months Ended		Year Ended	
	31.12.2025	30.09.2025	31.12.2024	31.12.2024	31.03.2025	31.03.2025
	Unaudited		Unaudited		Audited	
Total Income from Operations (Net)	169.94	163.45	111.79	489.99	275.67	418.06
Net Profit/(Loss) for the period (before Tax, Exceptional and/or Extraordinary Items)	42.07	39.55	24.18	115.48	61.13	89.54
Net Profit/(Loss) for the period before tax (after Exceptional and/or Extraordinary Items)	40.91	39.55	24.18	114.32	61.13	89.54
Net Profit/(Loss) for the period after tax (after Exceptional and/or Extraordinary Items)	38.87	25.74	17.81	96.25	41.37	63.24
Total Comprehensive Income for the period (Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income (after tax))	38.81	26.17	18.46	96.36	41.99	63.60
Paid up Equity Share Capital (Equity Share of Rs. 10/- each)	17.84	17.84	17.44	17.84	17.44	17.44
Earnings Per Share (Face Value of Rs. 10/-)						
(1) Basic (*Not Annualised):	21.79*	14.47*	10.21*	54.41*	24.70*	37.37
(2) Diluted (*Not Annualised):	19.94*	12.94*	9.95*	48.76*	24.46*	35.27

1. The above is an extract of the detailed format of statement of Unaudited Consolidated Financial Results for the quarter and nine months ended on December 31, 2025, filed with Stock Exchanges under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the said Financial Results are available on the Stock Exchange website at: www.bseindia.com and on the Company's website at: www.cstechai.com. The same could also be accessed by scanning the QR Code provided below.

2. The Unaudited Consolidated Financial Results of Ceinsys Tech Limited (the "Company") for the quarter and nine months ended on December 31, 2025 (the "Statement") were reviewed by Audit Committee and approved by Board of Directors at their meeting held on February 9, 2026. The Statutory auditors of the Company have carried out a limited review of the above results for the quarter and nine months ended December 31, 2025.

Sd/-
Mr. Kaushik Khona
Managing Director, India Operations
DIN: 00026597

Place : Mumbai
Date : February 9, 2026
For and on behalf of Board of directors
Ceinsys Tech Limited

Registered Office : Ceinsys Tech Ltd, 10/5, IT Park, Nagpur - 440022, Maharashtra, India. CIN: L7300MH1998PLC14790
www.cstechai.com | contactus@csstechai.com | +91 712 6782800

Pharma Inc calls for easier regulatory prescription

Industry says approval delays, weak clinical trial infra holding back sector

ANALI SINGH
Mumbai, 10 February

ILLUSTRATION: ANIYA MOHANTY

India's leading pharmaceutical industry veterans have made a strong case for faster, simpler and more predictable regulation. They warned that delays in approvals, weak clinical trial infrastructure and poor domestic acceptance of Indian innovation are holding the sector back. This comes at a time when global peers—particularly China—are moving rapidly up the value chain.



Speaking at a panel discussion on the past and future of Indian pharma at the launch of the book 'Made in India—The Story of Desh Bandhu Gupta, Lupin and Indian Pharma', industry stalwarts, including Dilip Shanghvi, managing director of Sun Pharma, Yusuf Hamied, chairman of Cipla, G V Prasad, managing director of Dr Reddy's Laboratories and Vinita Gupta, chief executive officer (CEO) of Lupin, said India must urgently reform its regulatory ecosystem. This would help it transition from a generics-led model to higher-value innovation.

Eyeing a growth pill

- Sun Pharma MD Dilip Shanghvi said regulatory delays, especially in clinical trials, push early-stage studies abroad
- Dr Reddy's Laboratories MD G V Prasad said India underestimated China, which built innovation strength through faster approvals
- Cipla Chairman Yusuf Hamied said Indian innovation suffers from poor domestic acceptance
- Lupin CEO Vinita Gupta said India can innovate without multi-billion-dollar R&D by leveraging its patient pool, regulatory reform and incentives

The industry veterans highlighted how regulatory delays, especially in clinical trial approvals, are forcing Indian companies to conduct early-stage studies overseas.

Shanghvi noted that Phase-I trials often get completed in countries such as Belgium or Australia before approvals come through in India, underscoring the need for smoother processes if the country wants to become an innovation hub.

He said the government's recent steps, including the production linked incentive-style PRIP scheme and plan to certify 1,000 clinical trial centres, signal intent, but execution will be key.

China emerged repeatedly as a point of comparison. Prasad said India has not done as well as China for years, seeing it mainly as a low-cost manufacturing base, while it quietly built a powerful innovation ecosystem.

He pointed to China's large reimbursed domestic market, faster regulatory clearance, rapid clinical development timelines and its success in attracting globally-trained biopharma leadership as critical advantages.

These factors, he said, have enabled Chinese firms to move beyond generics

into fast-follower and best-in-class innovation, a space that requires millions of dollars of investment per molecule and far higher risk tolerance.

"The panel stressed that 'fast follower' drugs should not be trivialised as incremental work."

Prasad described them as best-in-class innovations that demand expensive clinical trials, advanced medicinal chemistry and strong regulatory capabilities.

"This is a very different game from generics," he said, adding that innovation involves fewer but much larger bets compared with the multiple small bets, typical of generics.

Hamied traced India's pharma roots to policy choices that prioritised access over

monopoly, recalling the 1972 patent law changes that enabled domestic manufacturing of essential drugs.

While reiterating his support for science being rewarded through royalties, he argued against monopolistic pricing and said innovation in India continues to face a major hurdle: acceptability.

Indian doctors, he said, often remain sceptical of domestically-developed new drugs, asking why multinational companies have not launched them first.

Academia-industry collaboration also came under focus.

Sharma said India has a cultural resistance to being "first in the world" and a reluctance to accept failure, both of which stifle innovation.

He stressed that applied research must ultimately find its way into industry and markets, and called for greater focus on areas such as biotransformation, formulation engineering and sustainable manufacturing. Here, India remains overly dependent on imports, particularly from China.

Gupta argued that India does not need to replicate the multi-billion-dollar research and development (R&D) spending of global pharma giants to innovate.

Instead, she said, companies can leverage India's large patient pool, improving regulatory pathways and government incentives to conduct faster development locally, establish proof of concept and then scale products globally.

She also highlighted opportunities in off-patent brands, speciality generics, biosimilars and novel formulations as lower-risk pathways to value creation.

While acknowledging that innovation requires significant capital and tolerance for failure, Shanghvi said Indian companies need a few visible success stories to build confidence across the industry.

Recent out-licensing deals, he said, show that Indian innovation can attract global interest if supported by the right ecosystem.

The overarching message from the panel was clear: without regulatory agility, better clinical infrastructure, stronger industry-academia links and a shift in mindset towards risk-taking and acceptance of failure, India risks ceding ground to faster-moving peers.

CKYC ID: One KEY for All Your KYC Needs



Unique 14-digit CKYC ID issued by CKYC Records Registry

HOW IT WORKS?

- Submit KYC details to your bank
- Bank uploads KYC details on Central KYC Records Registry
- Can be used across banks & financial institutions

Know your CKYC ID

- Missed call: 7799022129 or
- Online: www.kycindia.in

KEY BENEFITS

- 1 Open accounts easily with different banks/financial institutions
- 1 Simplifies KYC Update: KYC updated with one bank, gets updated in your all other banks/financial institutions through CKYC

Simple. Secure. Standardised.



Issued in public interest by भारतीय रिज़र्व बैंक RESERVE BANK OF INDIA www.rbi.org.in

APPOINTMENTS

Driving the delivery and growth of markets.

As a cornerstone of India's financial market infrastructure, MCX has been integral to India's economic growth, strengthening the markets through robust price discovery and effective risk management for the commodity ecosystem. Step into a leadership role that drives those markets into the future through a continued focus on innovation and governance.

LEADERSHIP OPENINGS

EXECUTIVE DIRECTOR Critical Operations (ED1)

Lead technology, cybersecurity, trading infrastructure and digital transformation at MCX, building future-ready market infrastructure at a national scale. Drive innovation in emerging technologies while safeguarding system resilience, reliability, integrity and regulatory compliance.

Apply at: ED1_MCX@sheffieldhaworth.com before 3 March 2026

EXECUTIVE DIRECTOR Regulatory, Compliance, Risk Management & Investor Grievances (ED2)

Provide enterprise-wide leadership across operational excellence, investigations, investor grievances, risk, regulatory compliance and governance. Engage closely with key stakeholders to uphold integrity, transparency and institutional credibility.

Apply at: ED2_MCX@sheffieldhaworth.com before 3 March 2026

EXECUTIVE DIRECTOR Business (ED3)

Lead business strategy and ecosystem relationships to increase diversity of participation and product development, liquidity enhancement and revenue diversification within a regulated market infrastructure, while maintaining strong brand positioning.

Apply at: ED3_MCX@sheffieldhaworth.com before 10 March 2026

LOCATION : MUMBAI


Multi Commodity Exchange of India Limited (MCX) is India's largest stock exchange in the commodity derivatives segment, recognised under the Securities Contracts (Regulation) Act, 1956, and regulated by SEBI as a Market Infrastructure Institution (MI).



MCX
METAL & ENERGY
Trade with Trust

CS TECH AI Enabling Possibilities

Ceinsys Tech delivers strong revenue growth in Q3 FY26 with consistently improving EBITDA margins



- 27 Years of Legacy
- 200+ Customers
- Global Footprint Presence across US, Europe and India
- Geospatial Services
- Technology Solutions
- Automotive Engineering

Operational and other Highlights: Confirmed Order Book as on Dec-31, 2025: ₹999 Cr; Geospatial & Engineering Services revenue up by 76.5% YoY; Technology Solutions revenue up by 79.41% YoY; Major Milestones this Quarter: New order book during quarter: ₹170 Cr; Strategic Partnership with Tech-AI & Arctosky (Singapore) - Leveraging global expertise of Enterprise Geospatial Programs.

EXTRACT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2025

Particulars	CONSOLIDATED					
	Quarter Ended		Nine Months Ended		Year Ended	
	31.12.2025	30.09.2025	31.12.2024	31.12.2024	31.12.2024	31.03.2025
Total Income from Operations (Net)	169.94	163.45	111.79	489.99	275.67	418.06
Net Profit/(Loss) for the period (before Tax, Exceptional and/or Extraordinary Items)	42.07	39.55	24.18	115.48	61.13	89.54
Net Profit/(Loss) for the period before tax (after Exceptional and/or Extraordinary Items)	40.91	39.55	24.18	114.32	61.13	89.54
Net Profit/(Loss) for the period after tax (after Exceptional and/or Extraordinary Items)	38.87	25.74	17.81	96.25	41.37	63.24
Total Comprehensive Income for the period (Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income (after tax))	38.81	26.17	18.46	96.36	41.99	63.60
Paid up Equity Share Capital (Equity Share of Rs. 10/- each)	17.84	17.84	17.44	17.84	17.44	17.44
Earnings Per Share (Face Value of Rs. 10/-)						
(1) Basic (*Not Annualised):	21.79*	14.47*	10.21*	54.41*	24.70*	37.37
(2) Diluted (**Not Annualised):	19.94*	12.94*	9.95*	48.76*	24.46*	35.27

1. The above is an extract of the detailed format of statement of Unaudited Consolidated Financial Results for the quarter and nine months ended on December 31, 2025, filed with Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the said Financial Results are available on the Stock Exchange website at: www.bseindia.com and on the Company's website at: www.cstechai.com. The same could also be accessed by scanning the QR Code provided below.

2. The Unaudited Consolidated Financial Results of Ceinsys Tech Limited (the "Company") for the quarter and nine months ended on December 31, 2025 (the "Statement") were reviewed by Audit Committee and approved by Board of Directors at their meeting held on February 9, 2026. The Statutory auditors of the Company have carried out a limited review of the above results for the quarter and nine months ended December 31, 2025.

Sd/-
Mr. Kaushik Khona
Managing Director, India Operations
DIN: 00026597
Place : Mumbai
Date : February 9, 2026
For and on behalf of Board of directors
Ceinsys Tech Limited
Registered Office : Ceinsys Tech Ltd, 10/S, IT Park, Nagpur - 440022, Maharashtra, India. CIN: L7300MH1998PLC14790
www.cstechai.com | contactus@csstechai.com | +91 712 6782800

Pharma Inc calls for easier regulatory prescription

Industry says approval delays, weak clinical trial infra holding back sector

ANALI SINGH
Mumbai, 10 February

ILLUSTRATION: ANIYA MOHANTY

India's leading pharmaceutical industry veterans have made a strong case for faster, simpler and more predictable regulations. They warned that delays in approvals, weak clinical trial infrastructure and poor domestic acceptance of Indian innovation are holding the sector back. This comes at a time when global peers—particularly China—are moving rapidly up the value chain.



Speaking at a panel discussion on the past and future of Indian pharma at the launch of the book 'Made in India—The Story of Desh Bandhu Gupta, Lupin and Indian Pharma', industry stalwarts, including Dilip Shanghvi, managing director of Sun Pharma, Yusuf Hamied, chairman of Cipla, G V Prasad, managing director of Dr Reddy's Laboratories and Vinita Gupta, chief executive officer (CEO) of Lupin, said India must urgently reform its regulatory ecosystem. This would help it transition from a generics-led model to higher-value innovation.

The industry veterans highlighted how regulatory delays, especially in clinical trial approvals, are forcing Indian companies to conduct early-stage studies overseas.

Shanghvi noted that Phase-I trials often get completed in countries such as Belgium or Australia before approvals come through in India, underscoring the need for smoother processes if the country wants to become an innovation hub.

Eyeing a growth pill

- Sun Pharma MD Dilip Shanghvi said regulatory delays, especially in clinical trials, push early-stage studies abroad
- Dr Reddy's Laboratories MD G V Prasad said India underestimated China, which built innovation strength through faster approvals
- Cipla Chairman Yusuf Hamied said Indian innovation suffers from poor domestic acceptance
- Lupin CEO Vinita Gupta said India can innovate without multi-billion-dollar R&D by leveraging its patient pool, regulatory reform and incentives

into fast-follower and best-in-class innovation, a space that requires millions of dollars of investment per molecule and far higher risk tolerance.

The panel stressed that "fast follower" drugs should not be trivialised as incremental work.

Prasad described them as best-in-class innovations that demand expensive clinical trials, advanced medicinal chemistry and strong regulatory capabilities.

"This is a very different game from generics," he said, adding that innovation involves fewer but much larger bets compared with the multiple small bets, typical of generics.

Hamied traced India's pharma roots to policy choices that prioritised access over

monopoly, recalling the 1972 patent law changes that enabled domestic manufacturing of essential drugs.

While reiterating his support for science being rewarded through royalties, he argued against monopolistic pricing and said innovation in India continues to face a major hurdle: acceptability.

Indian doctors, he said, often remain sceptical of domestically-developed new drugs, asking why multinational companies have not launched them first.

Academia-industry collaboration also came under focus.

Sharma said India has a cultural resistance to being "first in the world" and a reluctance to accept failure, both of which stifle innovation.

He stressed that applied research must ultimately find its way into industry and markets, and called for greater focus on areas such as biotransformation, formulation engineering and sustainable manufacturing. Here, India remains overly dependent on imports, particularly from China.

Gupta argued that India does not need to replicate the multi-billion-dollar research and development (R&D) spending of global pharma giants to innovate.

Instead, she said, companies can leverage India's large patient pool, improving regulatory pathways and government incentives to conduct faster development locally, establish proof of concept and then scale products globally.

She also highlighted opportunities in off-patent brands, specialty generics, biosimilars and novel formulations as lower-risk pathways to value creation.

While acknowledging that innovation requires significant capital and tolerance for failure, Shanghvi said Indian companies need a few visible success stories to build confidence across the industry.

Recent out-licensing deals, he said, show that Indian innovation can attract global interest if supported by the right ecosystem.

The overarching message from the panel was clear: without regulatory agility, better clinical infrastructure, stronger industry-academia links and a shift in mindset towards risk-taking and acceptance of failure, India risks ceding ground to faster-moving peers.

CKYC ID: One KEY for All Your KYC Needs



Unique 14-digit CKYC ID issued by CKYC Records Registry

HOW IT WORKS?

- Submit KYC details to your bank
- Bank uploads KYC details on Central KYC Records Registry
- Can be used across banks & financial institutions

Know your CKYC ID

- Missed call: 7799021219 or
- Online: www.kycindia.in

KEY BENEFITS

- 1 Open accounts easily with different banks/financial institutions
- 1 Simplifies KYC Update: KYC updated with one bank, gets updated in your all other banks/financial institutions through CKYC

Simple. Secure. Standardised.



Issued in public interest by भारतीय रिज़र्व बैंक RESERVE BANK OF INDIA www.rbi.org.in

APPOINTMENTS

Driving the delivery and growth of markets.

As a cornerstone of India's financial market infrastructure, MCX has been integral to India's economic growth, strengthening the markets through robust price discovery and effective risk management for the commodity ecosystem. Step into a leadership role that drives those markets into the future through a continued focus on innovation and governance.

LEADERSHIP OPENINGS

- EXECUTIVE DIRECTOR
Critical Operations (ED1)

Lead technology, cybersecurity, trading infrastructure and digital transformation at MCX, building future-ready market infrastructure at a national scale. Drive innovation in emerging technologies while safeguarding system resilience, reliability, integrity and regulatory compliance.

Apply at: ED1_MCX@sheffieldhaworth.com before 3 March 2026

- EXECUTIVE DIRECTOR
Regulatory, Compliance, Risk Management & Investor Grievances (ED2)

Provide enterprise-wide leadership across operational excellence, investigations, investor grievances, risk, regulatory compliance and governance. Engage closely with key stakeholders to uphold integrity, transparency and institutional credibility.

Apply at: ED2_MCX@sheffieldhaworth.com before 3 March 2026

- EXECUTIVE DIRECTOR
Business (ED3)

Lead business strategy and ecosystem relationships to increase diversity of participation and product development, liquidity enhancement and revenue diversification within a regulated market infrastructure, while maintaining strong brand positioning.

Apply at: ED3_MCX@sheffieldhaworth.com before 10 March 2026

LOCATION : MUMBAI

Multi Commodity Exchange of India Limited (MCX) is India's largest stock exchange in the commodity derivatives segment, recognised under the Securities Contracts (Regulation) Act, 1956, and regulated by SEBI as a Market Infrastructure Institution (MI).



MCX
METAL & ENERGY
Trade with Trust

Ceinsys Tech delivers strong revenue growth in Q3 FY26 with consistently improving EBITDA margins

Quarterly Revenue (INR Cr) and EBITDA Margins (%)

Quarter	Revenue (INR Cr)	YoY Growth (%)	EBITDA (INR Cr)	YoY Growth (%)	Patent Revenue (INR Cr)	YoY Growth (%)
Q1 FY25	73.8	17.92%	11.8	19.0%	169.9	118%
Q2 FY25	90.0	18.6%	142.4	88%	163.5	118%
Q3 FY25	111.8	19.0%	156.6	88%	163.5	118%
Q4 FY25	142.4	18.80%	193.2%	88%	163.5	118%
Q1 FY26	156.6	19.32%	21.79%	88%	163.5	118%
Q2 FY26	163.5	21.79%	23.48%	88%	163.5	118%
Q3 FY26	169.9	23.48%	23.48%	88%	163.5	118%

Q3 FY26 Revenue: ₹169.94 Cr (YoY 52%) | Q3 FY26 EBITDA: ₹39.91 Cr (YoY 88%) | Q3 FY26 PAT: ₹38.87 Cr (YoY 118%)

- 27 Years of Legacy
- 200+ Customers
- Global Footprint Presence across US, Europe and India
- Geospatial Services
- Technology Solutions
- Automotive Engineering

Operational and other Highlights

Confirmed Order Book as on Dec-31, 2025: ₹999 Cr

Geospatial & Engineering Services revenue up by 76.5% YoY

Technology Solutions revenue up by 79.41% YoY

Major Milestones this Quarter

- New order book during quarter: ₹170 Cr
- Strategic Partnership with Tech-4 & Arctosky (Singapore)
- Renewed global presence of Enterprise Geospatial Programs

EXTRACT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2025

Particulars	CONSOLIDATED					
	Quarter Ended		Nine Months Ended		Year Ended	
	31.12.2025	30.09.2025	31.12.2024	31.12.2024	31.12.2024	31.03.2025
Total Income from Operations (Net)	169.94	163.45	111.79	489.99	275.67	418.06
Net Profit/(Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	42.07	39.55	24.18	115.48	61.13	89.54
Net Profit/(Loss) for the period before tax (after Exceptional and/or Extraordinary items)	40.91	39.55	24.18	114.32	61.13	89.54
Net Profit/(Loss) for the period after tax (after Exceptional and/or Extraordinary items)	38.87	25.74	17.81	96.25	41.37	63.24
Total Comprehensive Income for the period (Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income (after tax))	38.81	26.17	18.46	96.36	41.99	63.60
Paid up Equity Share Capital (Equity Share of Rs. 10/- each)	17.84	17.84	17.44	17.84	17.44	17.44
Earnings Per Share (Face Value of Rs. 10/-)						
(1) Basic (*Not Annualised):	21.79*	14.47*	10.21*	54.41*	24.70*	37.37
(2) Diluted (**Not Annualised):	19.94*	12.94*	9.95*	48.76*	24.46*	35.27

1. The above is an extract of the detailed format of statement of Unaudited Consolidated Financial Results for the quarter and nine months ended on December 31, 2025, filed with Stock Exchanges under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the said Financial Results are available on the Stock Exchange website at: www.bseindia.com and on the Company's website at: www.cstechnai.com. The same could also be accessed by scanning the QR Code provided below.

2. The Unaudited Consolidated Financial Results of Ceinsys Tech Limited (the "Company") for the quarter and nine months ended on December 31, 2025 (the "Statement") were reviewed by Audit Committee and approved by Board of Directors at their meeting held on February 9, 2026. The Statutory auditors of the Company have carried out a limited review of the above results for the quarter and nine months ended December 31, 2025.

Sd/-
Mr. Kaushik Khona
Managing Director, India Operations
DIN: 00026597

Place : Mumbai
Date : February 9, 2026
For and on behalf of Board of directors
Ceinsys Tech Limited

Registered Office : Ceinsys Tech Ltd, 10/5, IT Park, Nagpur - 440022, Maharashtra, India. CIN: L7300MH1998PLC14790
www.cstech.ai | contactus@cstech.ai | +91 712 6782800

Pharma Inc calls for easier regulatory prescription

Industry says approval delays, weak clinical trial infra holding back sector

ANALI SINGH
Mumbai, 10 February

ILLUSTRATION: ANIYA MOHANTY

India's leading pharmaceutical industry veterans have made a strong case for faster, simpler and more predictable regulations. They warned that delays in approvals, weak clinical trial infrastructure and poor domestic acceptance of Indian innovation are holding the sector back. This comes at a time when global peers—particularly China—are moving rapidly up the value chain.



Speaking at a panel discussion on the past and future of Indian pharma at the launch of the book 'Made in India—The Story of Desh Bandhu Gupta, Lupin and Indian Pharma', industry stalwarts, including Dilip Shanghvi, managing director of Sun Pharma, Yusuf Hamied, chairman of Cipla, G V Prasad, managing director of Dr Reddy's Laboratories and Vinita Gupta, chief executive officer (CEO) of Lupin, said India must urgently reform its regulatory ecosystem. This would help it transition from a generics-led model to higher-value innovation.

Eyeing a growth pill

- Sun Pharma MD Dilip Shanghvi said regulatory delays, especially in clinical trials, push early-stage studies abroad
- Dr Reddy's Laboratories MD G V Prasad said India underestimated China, which built innovation strength through faster approvals
- Cipla Chairman Yusuf Hamied said Indian innovation suffers from poor domestic acceptance
- Lupin CEO Vinita Gupta said India can innovate without multi-billion-dollar R&D by leveraging its patient pool, regulatory reform and incentives

The industry veterans highlighted how regulatory delays, especially in clinical trial approvals, are forcing Indian companies to conduct early-stage studies overseas. Shanghvi noted that Phase-I trials often get completed in countries such as Belgium or Australia before approvals come through in India, underscoring the need for smoother processes if the country wants to become an innovation hub.

He said the government's recent steps, including the production linked incentive-style PRIP scheme and plan to certify 1,000 clinical trial centres, signal intent, but execution will be key.

China emerged repeatedly as a point of comparison. Prasad said India has underestimated China for years, seeing it mainly as a low-cost manufacturing base, while it quietly built a powerful innovation ecosystem.

He pointed to China's large reimbursed domestic market, faster regulatory clearances, rapid clinical development timelines and its success in attracting globally-trained biopharma leadership as critical advantages.

These factors, he said, have enabled Chinese firms to move beyond generics

into fast-follower and best-in-class innovation, a space that requires millions of dollars of investment per molecule and far higher risk tolerance.

The panel stressed that "fast follower" drugs should not be trivialised as incremental work. Prasad described them as best-in-class innovations that demand expensive clinical trials, advanced medicinal chemistry and strong regulatory capabilities.

"This is a very different game from generics," he said, adding that innovation involves fewer but much larger bets compared with the multiple small bets, typical of generics.

Hamied traced India's pharma roots to policy choices that prioritised access over

monopoly, recalling the 1972 patent law changes that enabled domestic manufacturing of essential drugs.

While reiterating his support for science being rewarded through royalties, he argued against monopolistic pricing and said innovation in India continues to face a major hurdle: acceptability.

Indian doctors, he said, often remain sceptical of domestically-developed new drugs, asking why multinational companies have not launched them first.

Academia-industry collaboration also came under focus. Sharma said India has a cultural resistance to being "first in the world" and a reluctance to accept failure, both of which stifle innovation.

He stressed that applied research must ultimately find its way into industry and markets, and called for greater focus on areas such as biotransformation, formulation engineering and sustainable manufacturing. Here, India remains overly dependent on imports, particularly from China.

Gupta argued that India does not need to replicate the multi-billion-dollar research and development (R&D) spending of global pharma giants to innovate.

Instead, she said, companies can leverage India's large patient pool, improving regulatory pathways and government incentives to conduct faster development locally, establish proof of concept and then scale products globally.

She also highlighted opportunities in off-patent brands, specialty generics, biosimilars and novel formulations as lower-risk pathways to value creation.

While acknowledging that innovation requires significant capital and tolerance for failure, Shanghvi said Indian companies need a few visible success stories to build confidence across the industry.

Recent out-licensing deals, he said, show that Indian innovation can attract global interest if supported by the right ecosystem. The overarching message from the panel was clear: without regulatory agility, better clinical infrastructure, stronger industry-academia links and a shift in mindset towards risk-taking and acceptance of failure, India risks ceding ground to faster-moving peers.

CKYC ID: One KEY for All Your KYC Needs



Unique 14-digit CKYC ID issued by CKYC Records Registry

HOW IT WORKS?

- Submit KYC details to your bank
- Bank uploads KYC details on Central KYC Records Registry
- Can be used across banks & financial institutions

Know your CKYC ID

- Missed call: 7799022129 or
- Online: www.kycindia.in

KEY BENEFITS

- 1 Open accounts easily with different banks/financial institutions
- 1 Simplifies KYC Update: KYC updated with one bank, gets updated in your all other banks/financial institutions through CKYC

Simple. Secure. Standardised.



Issued in public interest by भारतीय रिज़र्व बैंक RESERVE BANK OF INDIA www.rbi.org.in

APPOINTMENTS

Driving the delivery and growth of markets.

As a cornerstone of India's financial market infrastructure, MCX has been integral to India's economic growth, strengthening the markets through robust price discovery and effective risk management for the commodity ecosystem. Step into a leadership role that drives those markets into the future through a continued focus on innovation and governance.

LEADERSHIP OPENINGS

- EXECUTIVE DIRECTOR
Critical Operations (ED1)

Lead technology, cybersecurity, trading infrastructure and digital transformation at MCX, building future-ready market infrastructure at a national scale. Drive innovation in emerging technologies while safeguarding system resilience, reliability, integrity and regulatory compliance.

Apply at: ED1_MCX@sheffieldhaworth.com before 3 March 2026

- EXECUTIVE DIRECTOR
Regulatory, Compliance, Risk Management & Investor Grievances (ED2)

Provide enterprise-wide leadership across operational excellence, investigations, investor grievances, risk, regulatory compliance and governance. Engage closely with key stakeholders to uphold integrity, transparency and institutional credibility.

Apply at: ED2_MCX@sheffieldhaworth.com before 3 March 2026

- EXECUTIVE DIRECTOR
Business (ED3)

Lead business strategy and ecosystem relationships to increase diversity of participation and product development, liquidity enhancement and revenue diversification within a regulated market infrastructure, while maintaining strong brand positioning.

Apply at: ED3_MCX@sheffieldhaworth.com before 10 March 2026

LOCATION : MUMBAI


Multi Commodity Exchange of India Limited (MCX) is India's largest stock exchange in the commodity derivatives segment, recognised under the Securities Contracts (Regulation) Act, 1956, and regulated by SEBI as a Market Infrastructure Institution (MI).



MCX
METAL & ENERGY
Trade with Trust

CS TECH AI Envisioning Possibilities

Ceinsys Tech delivers strong revenue growth in Q3 FY26 with consistently improving EBITDA margins



- 27 Years of Legacy
- 200+ Customers
- Global Footprint Presence across US, Europe and India
- Geospatial Services
- Technology Solutions
- Automotive Engineering

Q3 FY26 Revenue: ₹169.94 Cr (YoY 52%) | Q3 FY26 EBITDA: ₹39.91 Cr (YoY 88%) | Q3 FY26 PAT: ₹38.87 Cr (YoY 118%)

For Nine months ended December 31, 2025

Operational and other Highlights	Confirmed Order Book as on Dec. 31, 2025: ₹999 Cr	Geospatial & Engineering Services revenue up by: 76.5% YoY	Technology Solutions revenue up by: 79.41% YoY	Major Milestones this Quarter: New order book during quarter: ₹170 Cr
----------------------------------	---	--	--	---

EXTRACT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2025

Particulars	CONSOLIDATED				
	Quarter Ended		Nine Months Ended		Year Ended
	31.12.2025	30.09.2025	31.12.2024	31.12.2024	31.03.2025
Total Income from Operations (Net)	169.94	163.45	111.79	489.99	275.67
Net Profit/(Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	42.07	39.55	24.18	115.48	61.13
Net Profit/(Loss) for the period before tax (after Exceptional and/or Extraordinary items)	40.91	39.55	24.18	114.32	61.13
Net Profit/(Loss) for the period after tax (after Exceptional and/or Extraordinary items)	38.87	25.74	17.81	96.25	41.37
Total Comprehensive Income for the period (Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income (after tax))	38.81	26.17	18.46	96.36	41.99
Paid up Equity Share Capital (Equity Share of Rs. 10/- each)	17.84	17.84	17.44	17.84	17.44
Earnings Per Share (Face Value of Rs. 10/-)	21.79*	14.47*	10.21*	54.41*	24.70*
(1) Basic (*Not Annualised)	19.94*	12.94*	9.95*	48.76*	24.46*
(2) Diluted (*Not Annualised)					35.27

1. The above is an extract of the detailed format of statement of Unaudited Consolidated Financial Results for the quarter and nine months ended on December 31, 2025, filed with Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full form of the said Financial Results are available on the Stock Exchange website at: www.bseindia.com and on the Company's website at: www.cstechai.com. The same could also be accessed by scanning the QR Code provided below.

2. The Unaudited Consolidated Financial Results of Ceinsys Tech Limited (the "Company") for the quarter and nine months ended on December 31, 2025 (the "Statement") were reviewed by Audit Committee and approved by Board of Directors at their meeting held on February 9, 2026. The Statutory auditors of the Company have carried out a limited review of the above results for the quarter and nine months ended December 31, 2025.

Sd/-
Mr. Kaushik Khona
Managing Director, India Operations
DIN: 00026597

Place : Mumbai
Date : February 9, 2026
For and on behalf of Board of directors
Ceinsys Tech Limited

Registered Office : Ceinsys Tech Ltd, 10/5, IT Park, Nagpur - 440022, Maharashtra, India. CIN: L7300MH1998PLC14790
www.cstechai | contactus@csstechai | +91 712 6782800

Pharma Inc calls for easier regulatory prescription

Industry says approval delays, weak clinical trial infra holding back sector

ANALI SINGH
Mumbai, 10 February

ILLUSTRATION: ANIYA MOHANTY

India's leading pharmaceutical industry veterans have made a strong case for faster, simpler and more predictable regulation. They warned that delays in approvals, weak clinical trial infrastructure and poor domestic acceptance of Indian innovation are holding the sector back. This comes at a time when global peers—particularly China—are moving rapidly up the value chain.



Speaking at a panel discussion on the past and future of Indian pharma at the launch of the book 'Made in India—The Story of Desh Bandhu Gupta, Lupin and Indian Pharma', industry stalwarts, including Dilip Shanghvi, managing director of Sun Pharma, Yusuf Hamied, chairman of Cipla, G V Prasad, managing director of Dr Reddy's Laboratories and Vinita Gupta, chief executive officer (CEO) of Lupin, said India must urgently reform its regulatory ecosystem. This would help it transition from a generics-led model to higher-value innovation.

Eyeing a growth pill

- Sun Pharma MD Dilip Shanghvi said regulatory delays, especially in clinical trials, push early-stage studies abroad
- Dr Reddy's Laboratories MD G V Prasad said India underestimated China, which built innovation strength through faster approvals
- Cipla Chairman Yusuf Hamied said Indian innovation suffers from poor domestic acceptance
- Lupin CEO Vinita Gupta said India can innovate without multi-billion-dollar R&D by leveraging its patient pool, regulatory reform and incentives

The industry veterans highlighted how regulatory delays, especially in clinical trial approvals, are forcing Indian companies to conduct early-stage studies overseas. Shanghvi noted that Phase-I trials often get completed in countries such as Belgium or Australia before approvals come through in India, underscoring the need for smoother processes if the country wants to become an innovation hub.

He said the government's recent steps, including the production linked incentive-style PRIP scheme and plan to certify 1,000 clinical trial centres, signal intent, but execution will be key.

China emerged repeatedly as a point of comparison. Prasad said India has not done as well as China for years, seeing it mainly as a low-cost manufacturing base, while it quietly built a powerful innovation ecosystem.

He pointed to China's large reimbursed domestic market, faster regulatory clearance, rapid clinical development timelines and its success in attracting globally-trained biopharma leadership as critical advantages.

These factors, he said, have enabled Chinese firms to move beyond generics

into fast-follower and best-in-class innovation, a space that requires millions of dollars of investment per molecule and far higher risk tolerance.

The panel stressed that "fast follower" drugs should not be trivialised as incremental work.

Prasad described them as best-in-class innovations that demand expensive clinical trials, advanced medicinal chemistry and strong regulatory capabilities.

"This is a very different game from generics," he said, adding that innovation involves fewer but much larger bets compared with the multiple small bets, typical of generics.

Hamied traced India's pharma roots to policy choices that prioritised access over

monopoly, recalling the 1972 patent law changes that enabled domestic manufacturing of essential drugs.

While reiterating his support for science being rewarded through royalties, he argued against monopolistic pricing and said innovation in India continues to face a major hurdle: acceptability.

Indian doctors, he said, often remain sceptical of domestically-developed new drugs, asking why multinational companies have not launched them first.

Academia-industry collaboration also came under focus.

Sharma said India has a cultural resistance to being "first in the world" and a reluctance to accept failure, both of which stifle innovation.

He stressed that applied research must ultimately find its way into industry and markets, and called for greater focus on areas such as biotransformation, formulation engineering and sustainable manufacturing. Here, India remains overly dependent on imports, particularly from China.

Gupta argued that India does not need to replicate the multi-billion-dollar research and development (R&D) spending of global pharma giants to innovate.

Instead, she said, companies can leverage India's large patient pool, improving regulatory pathways and government incentives to conduct faster development locally, establish proof of concept and then scale products globally.

She also highlighted opportunities in off-patent brands, specialty generics, biosimilars and novel formulations as lower-risk pathways to value creation.

While acknowledging that innovation requires significant capital and tolerance for failure, Shanghvi said Indian companies need a few visible success stories to build confidence across the industry.

Recent out-licensing deals, he said, show that Indian innovation can attract global interest if supported by the right ecosystem.

The overarching message from the panel was clear: without regulatory agility, better clinical infrastructure, stronger industry-academia links and a shift in mindset towards risk-taking and acceptance of failure, India risks ceding ground to faster-moving peers.

CKYC ID: One KEY for All Your KYC Needs



Unique 14-digit CKYC ID issued by CKYC Records Registry

HOW IT WORKS?

- Submit KYC details to your bank
- Bank uploads KYC details on Central KYC Records Registry
- Can be used across banks & financial institutions

Know your CKYC ID

- Missed call: 7799022129 or
- Online: www.ckycindia.in

KEY BENEFITS

- 1 Open accounts easily with different banks/financial institutions
- 1 Simplifies KYC Update: KYC updated with one bank, gets updated in your all other banks/financial institutions through CKYC

Simple. Secure. Standardised.



APPOINTMENTS

Driving the delivery and growth of markets.

As a cornerstone of India's financial market infrastructure, MCX has been integral to India's economic growth, strengthening the markets through robust price discovery and effective risk management for the commodity ecosystem. Step into a leadership role that drives those markets into the future through a continued focus on innovation and governance.

LEADERSHIP OPENINGS

- **EXECUTIVE DIRECTOR**
Critical Operations (ED1)

Lead technology, cybersecurity, trading infrastructure and digital transformation at MCX, building future-ready market infrastructure at a national scale. Drive innovation in emerging technologies while safeguarding system resilience, reliability, integrity and regulatory compliance.

Apply at: ED1_MCX@sheffieldhaworth.com before 3 March 2026

- **EXECUTIVE DIRECTOR**

Regulatory, Compliance, Risk Management & Investor Grievances (ED2)

Provide enterprise-wide leadership across operational excellence, investigations, investor grievances, risk, regulatory compliance and governance. Engage closely with key stakeholders to uphold integrity, transparency and institutional credibility.

Apply at: ED2_MCX@sheffieldhaworth.com before 3 March 2026

- **EXECUTIVE DIRECTOR**
Business (ED3)

Lead business strategy and ecosystem relationships to increase diversity of participation and product development, liquidity enhancement and revenue diversification within a regulated market infrastructure, while maintaining strong brand positioning.

Apply at: ED3_MCX@sheffieldhaworth.com before 10 March 2026

LOCATION : MUMBAI

Multi Commodity Exchange of India Limited (MCX) is India's largest stock exchange in the commodity derivatives segment, recognised under the Securities Contracts (Regulation) Act, 1956, and regulated by SEBI as a Market Infrastructure Institution (MI).



Ceinsys Tech delivers strong revenue growth in Q3 FY26 with consistently improving EBITDA margins

Quarterly Revenue (INR Cr) and EBITDA Margins (%)

Quarter	Revenue (INR Cr)	YoY Growth (%)	EBITDA (INR Cr)	YoY Growth (%)	EBITDA Margin (%)	YoY Growth (%)
Q1 FY25	73.8	17.92%	39.9	88%	52%	52%
Q2 FY25	90.0	18.6%	39.9	88%	52%	52%
Q3 FY25	111.8	19.0%	39.9	88%	52%	52%
Q4 FY25	142.4	18.80%	39.9	88%	52%	52%
Q1 FY26	156.6	19.32%	38.87	88%	52%	52%
Q2 FY26	163.5	21.79%	38.87	88%	52%	52%
Q3 FY26	169.9	23.48%	38.87	88%	52%	52%

- 27 Years of Legacy
- 200+ Customers
- Global Footprint Presence across US, Europe and India
- Geospatial Services
- Technology Solutions
- Automotive Engineering

Operational and other Highlights

Confirmed Order Book as on Dec 31, 2025

₹999 Cr

Geospatial & Engineering Services revenue up by

76.5% YoY

Technology Solutions revenue up by

79.41% YoY

Major Milestones this Quarter

New order book during quarter

₹170 Cr

EXTRACT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2025

Particulars	CONSOLIDATED					
	Quarter Ended		Nine Months Ended		Year Ended	
	31.12.2025	30.09.2025	31.12.2024	31.12.2024	31.03.2025	31.03.2025
	Unaudited		Unaudited		Audited	
Total Income from Operations (Net)	169.94	163.45	111.79	489.99	275.67	418.06
Net Profit/(Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	42.07	39.55	24.18	115.48	61.13	89.54
Net Profit/(Loss) for the period before tax (after Exceptional and/or Extraordinary items)	40.91	39.55	24.18	114.32	61.13	89.54
Net Profit/(Loss) for the period after tax (after Exceptional and/or Extraordinary items)	38.87	25.74	17.81	96.25	41.37	63.24
Total Comprehensive Income for the period (Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income (after tax))	38.81	26.17	18.46	96.36	41.99	63.60
Paid up Equity Share Capital (Equity Share of Rs. 10/- each)	17.84	17.84	17.44	17.84	17.44	17.44
Earnings Per Share (Face Value of Rs. 10/-)						
(1) Basic (*Not Annualised):	21.79*	14.47*	10.21*	54.41*	24.70*	37.37
(2) Diluted (*Not Annualised):	19.94*	12.94*	9.95*	48.76*	24.46*	35.27

1. The above is an extract of the detailed format of statement of Unaudited Consolidated Financial Results for the quarter and nine months ended on December 31, 2025, filed with Stock Exchanges under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the said Financial Results are available on the Stock Exchange website at: www.bseindia.com and on the Company's website at: www.cstechnai.com. The same could also be accessed by scanning the QR Code provided below.

2. The Unaudited Consolidated Financial Results of Ceinsys Tech Limited (the "Company") for the quarter and nine months ended on December 31, 2025 (the "Statement") were reviewed by Audit Committee and approved by Board of Directors at their meeting held on February 9, 2026. The Statutory auditors of the Company have carried out a limited review of the above results for the quarter and nine months ended December 31, 2025.

Sd/-
Mr. Kaushik Khona
Managing Director, India Operations
DIN: 00026597

Place : Mumbai For and on behalf of Board of directors Managing Director, India Operations
Date : February 9, 2026 Ceinsys Tech Limited DIN: 00026597

Registered Office : Ceinsys Tech Ltd, 10/5, IT Park, Nagpur - 440022, Maharashtra, India. CIN: L72300MH1998PLC14790
www.cstech.ai contactus@cstech.ai +91 712 6782800

Pharma Inc calls for easier regulatory prescription

Industry says approval delays, weak clinical trial infra holding back sector

ANALI SINGH
Mumbai, 10 February

ILLUSTRATION: ANIYA MOHANTY

India's leading pharmaceutical industry veterans have made a strong case for faster, simpler and more predictable regulation. They warned that delays in approvals, weak clinical trial infrastructure and poor domestic acceptance of Indian innovation are holding the sector back. This comes at a time when global peers—particularly China—are moving rapidly up the value chain.



Speaking at a panel discussion on the past and future of Indian pharma at the launch of the book 'Made in India—The Story of Desh Bandhu Gupta, Lupin and Indian Pharma', industry stalwarts, including Dilip Shanghvi, managing director of Sun Pharma, Yusuf Hamied, chairman of Cipla, G V Prasad, managing director of Dr Reddy's Laboratories and Vinita Gupta, chief executive officer (CEO) of Lupin, said India must urgently reform its regulatory ecosystem. This would help it transition from a generics-led model to higher-value innovation.

The industry veterans highlighted how regulatory delays, especially in clinical trial approvals, are forcing Indian companies to conduct early-stage studies overseas.

Shanghvi noted that Phase-I trials often get completed in countries such as Belgium or Australia before approvals come through in India, underscoring the need for smoother processes if the country wants to become an innovation hub.

Eyeing a growth pill

- Sun Pharma MD Dilip Shanghvi said regulatory delays, especially in clinical trials, push early-stage studies abroad
- Dr Reddy's Laboratories MD G V Prasad said India underestimated China, which built innovation strength through faster approvals
- Cipla Chairman Yusuf Hamied said Indian innovation suffers from poor domestic acceptance
- Lupin CEO Vinita Gupta said India can innovate without multi-billion-dollar R&D by leveraging its patient pool, regulatory reform and incentives

into fast-follower and best-in-class innovation, a space that requires millions of dollars of investment per molecule and far higher risk tolerance.

"The panel stressed that 'fast follower' drugs should not be trivialised as incremental work.

Prasad described them as best-in-class innovations that demand expensive clinical trials, advanced medicinal chemistry and strong regulatory capabilities.

"This is a very different game from generics," he said, adding that innovation involves fewer but much larger bets compared with the multiple small bets, typical of generics.

Hamied traced India's pharma roots to policy choices that prioritised access over

monopoly, recalling the 1972 patent law changes that enabled domestic manufacturing of essential drugs.

While reiterating his support for science being rewarded through royalties, he argued against monopolistic pricing and said innovation in India continues to face a major hurdle: acceptability.

Indian doctors, he said, often remain sceptical of domestically-developed new drugs, asking why multinational companies have not launched them first.

Academia-industry collaboration also came under focus.

Sharma said India has a cultural resistance to being "first in the world" and a reluctance to accept failure, both of which stifle innovation.

He stressed that applied research must ultimately find its way into industry and markets, and called for greater focus on areas such as biotransformation, formulation engineering and sustainable manufacturing. Here, India remains overly dependent on imports, particularly from China.

Gupta argued that India does not need to replicate the multi-billion-dollar research and development (R&D) spending of global pharma giants to innovate.

Instead, she said, companies can leverage India's large patient pool, improving regulatory pathways and government incentives to conduct faster development locally, establish proof of concept and then scale products globally.

She also highlighted opportunities in off-patent brands, speciality generics, biosimilars and novel formulations as lower-risk pathways to value creation.

While acknowledging that innovation requires significant capital and tolerance for failure, Shanghvi said Indian companies need a few visible success stories to build confidence across the industry.

Recent out-licensing deals, he said, show that Indian innovation can attract global interest if supported by the right ecosystem.

The overarching message from the panel was clear: without regulatory agility, better clinical infrastructure, stronger industry-academia links and a shift in mindset towards risk-taking and acceptance of failure, India risks ceding ground to faster-moving peers.

CKYC ID: One KEY for All Your KYC Needs



Unique 14-digit CKYC ID issued by CKYC Records Registry

HOW IT WORKS?

- Submit KYC details to your bank
- Bank uploads KYC details on Central KYC Records Registry
- Can be used across banks & financial institutions

Know your CKYC ID

- Missed call: 7799022129 or
- Online: www.kycindia.in

KEY BENEFITS

- 1 Open accounts easily with different banks/financial institutions
- 1 Simplifies KYC Update: KYC updated with one bank, gets updated in your all other banks/financial institutions through CKYC

Simple. Secure. Standardised.



Issued in public interest by भारतीय रिज़र्व बैंक RESERVE BANK OF INDIA www.rbi.org.in

APPOINTMENTS

Driving the delivery and growth of markets.

As a cornerstone of India's financial market infrastructure, MCX has been integral to India's economic growth, strengthening the markets through robust price discovery and effective risk management for the commodity ecosystem. Step into a leadership role that drives those markets into the future through a continued focus on innovation and governance.

LEADERSHIP OPENINGS

- **EXECUTIVE DIRECTOR**
Critical Operations (ED1)

Lead technology, cybersecurity, trading infrastructure and digital transformation at MCX, building future-ready market infrastructure at a national scale. Drive innovation in emerging technologies while safeguarding system resilience, reliability, integrity and regulatory compliance.

Apply at: ED1_MCX@sheffieldhaworth.com before 3 March 2026

- **EXECUTIVE DIRECTOR**

Regulatory, Compliance, Risk Management & Investor Grievances (ED2)

Provide enterprise-wide leadership across operational excellence, investigations, investor grievances, risk, regulatory compliance and governance. Engage closely with key stakeholders to uphold integrity, transparency and institutional credibility.

Apply at: ED2_MCX@sheffieldhaworth.com before 3 March 2026

- **EXECUTIVE DIRECTOR**
Business (ED3)

Lead business strategy and ecosystem relationships to increase diversity of participation and product development, liquidity enhancement and revenue diversification within a regulated market infrastructure, while maintaining strong brand positioning.

Apply at: ED3_MCX@sheffieldhaworth.com before 10 March 2026

LOCATION : MUMBAI

Multi Commodity Exchange of India Limited (MCX) is India's largest stock exchange in the commodity derivatives segment, recognised under the Securities Contracts (Regulation) Act, 1956, and regulated by SEBI as a Market Infrastructure Institution (MI).



MCX
METAL & ENERGY
Trade with Trust

Ceinsys Tech delivers strong revenue growth in Q3 FY26 with consistently improving EBITDA margins

Quarterly Revenue (INR Cr) and EBITDA Margins (%)

Quarter	Revenue (INR Cr)	YoY Growth (%)
Q1 FY25	73.8	17.92%
Q2 FY25	90.0	18.6%
Q3 FY25	111.8	19.0%
Q4 FY25	142.4	18.80%
Q1 FY26	156.6	19.32%
Q2 FY26	163.5	21.79%
Q3 FY26	169.9	23.48%

27 Years of Legacy

200+ Customers

Global Footprint Presence across US, Europe and India

Operational and other Highlights

Confirmed Order Book as on Dec. 31, 2025

₹999 Cr

Geospatial & Engineering Services revenue up by

76.5% YoY

Technology Solutions revenue up by

79.41% YoY

Major Milestones this Quarter

New order book during quarter: **₹170 Cr**

Strategic Partnership with Tech4B & Anterisk (Singapore) - Renewed global presence of Enterprise Geospatial Programs

EXTRACT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2025

Particulars	CONSOLIDATED				Year Ended 31.03.2025
	Quarter Ended		Nine Months Ended		
	31.12.2025	30.09.2025	31.12.2024	30.09.2024	
Total Income from Operations (Net)	169.94	163.45	111.79	489.99	418.06
Net Profit/(Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	42.07	39.55	24.18	115.48	89.54
Net Profit/(Loss) for the period before tax (after Exceptional and/or Extraordinary items)	40.91	39.55	24.18	114.32	89.54
Net Profit/(Loss) for the period after tax (after Exceptional and/or Extraordinary items)	38.87	25.74	17.81	96.25	63.24
Total Comprehensive Income for the period (Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income (after tax))	38.81	26.17	18.46	96.36	63.60
Paid up Equity Share Capital (Equity Share of Rs. 10/- each)	17.84	17.84	17.44	17.84	17.44
Earnings Per Share (Face Value of Rs. 10/-)					
(1) Basic (*Not Annualised):	21.79*	14.47*	10.21*	54.41*	24.70*
(2) Diluted (**Not Annualised):	19.94*	12.94*	9.95*	48.76*	35.27

1. The above is an extract of the detailed format of statement of Unaudited Consolidated Financial Results for the quarter and nine months ended on December 31, 2025, filed with Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full form of the said Financial Results are available on the Stock Exchange website at: www.bseindia.com and on the Company's website at: www.cstechai.com. The same could also be accessed by scanning the QR Code provided below.

2. The Unaudited Consolidated Financial Results of Ceinsys Tech Limited (the "Company") for the quarter and nine months ended on December 31, 2025 (the "Statement") were reviewed by Audit Committee and approved by Board of Directors at their meeting held on February 9, 2026. The Statutory auditors of the Company have carried out a limited review of the above results for the quarter and nine months ended December 31, 2025.

Sd/-
Mr. Kaushik Khona
Managing Director, India Operations
DIN: 00026597

Place : Mumbai
Date : February 9, 2026
For and on behalf of Board of directors
Ceinsys Tech Limited

Registered Office : Ceinsys Tech Ltd, 10/5, IT Park, Nagpur - 440022, Maharashtra, India. CIN: L7300MH1998PLC14790
www.cstech.ai | contactus@csctech.ai | +91 712 6782800

Pharma Inc calls for easier regulatory prescription

Industry says approval delays, weak clinical trial infra holding back sector

ANALI SINGH
Mumbai, 10 February

ILLUSTRATION: ANIYA MOHANTY

India's leading pharmaceutical industry veterans have made a strong case for faster, simpler and more predictable regulation. They warned that delays in approvals, weak clinical trial infrastructure and poor domestic acceptance of Indian innovation are holding the sector back. This comes at a time when global peers—particularly China—are moving rapidly up the value chain.



Speaking at a panel discussion on the past and future of Indian pharma at the launch of the book 'Made in India—The Story of Desh Bandhu Gupta, Lupin and Indian Pharma', industry stalwarts, including Dilip Shanghvi, managing director of Sun Pharma, Yusuf Hamied, chairman of Cipla, G V Prasad, managing director of Dr Reddy's Laboratories and Vinita Gupta, chief executive officer (CEO) of Lupin, said India must urgently reform its regulatory ecosystem. This would help it transition from a generics-led model to higher-value innovation.

The industry veterans highlighted how regulatory delays, especially in clinical trial approvals, are forcing Indian companies to conduct early-stage studies overseas.

Shanghvi noted that Phase-I trials often get completed in countries such as Belgium or Australia before approvals come through in India, underscoring the need for smoother processes if the country wants to become an innovation hub.

Eyeing a growth pill

- Sun Pharma MD Dilip Shanghvi said regulatory delays, especially in clinical trials, push early-stage studies abroad
- Dr Reddy's Laboratories MD G V Prasad said India underestimated China, which built innovation strength through faster approvals
- Cipla Chairman Yusuf Hamied said Indian innovation suffers from poor domestic acceptance
- Lupin CEO Vinita Gupta said India can innovate without multi-billion-dollar R&D by leveraging its patient pool, regulatory reform and incentives

He said the government's recent steps, including the production linked incentive-style PRIP scheme and plan to certify 1,000 clinical trial centres, signal intent, but execution will be key.

China emerged repeatedly as a point of comparison. Prasad said India has underestimated China for years, seeing it mainly as a low-cost manufacturing base, while it quietly built a powerful innovation ecosystem.

into fast-follower and best-in-class innovation, a space that requires millions of dollars of investment per molecule and far higher risk tolerance.

The panel stressed that "fast follower" drugs should not be trivialised as incremental work.

Prasad described them as best-in-class innovations that demand expensive clinical trials, advanced medicinal chemistry and strong regulatory capabilities.

He pointed to China's large reimbursed domestic market, faster regulatory clearances, rapid clinical development timelines and its success in attracting globally-trained biopharma leadership as critical advantages.

"This is a very different game from generics," he said, adding that innovation involves fewer but much larger bets compared with the multiple small bets, typical of generics.

These factors, he said, have enabled Chinese firms to move beyond generic

Hamied traced India's pharma roots to policy choices that prioritised access over

monopoly, recalling the 1972 patent law changes that enabled domestic manufacturing of essential drugs.

While reiterating his support for science being rewarded through royalties, he argued against monopolistic pricing and said innovation in India continues to face a major hurdle: acceptability.

Indian doctors, he said, often remain sceptical of domestically-developed new drugs, asking why multinational companies have not launched them first.

Academia-industry collaboration also came under focus.

Sharma said India has a cultural resistance to being "first in the world" and a reluctance to accept failure, both of which stifle innovation.

He stressed that applied research must ultimately find its way into industry and markets, and called for greater focus on areas such as biotransformation, formulation engineering and sustainable manufacturing. Here, India remains overly dependent on imports, particularly from China.

Gupta argued that India does not need to replicate the multi-billion-dollar research and development (R&D) spending of global pharma giants to innovate.

Instead, she said, companies can leverage India's large patient pool, improving regulatory pathways and government incentives to conduct faster development locally, establish proof of concept and then scale products globally.

She also highlighted opportunities in off-patent brands, speciality generics, bio-similars and novel formulations as lower-risk pathways to value creation.

While acknowledging that innovation requires significant capital and tolerance for failure, Shanghvi said Indian companies need a few visible success stories to build confidence across the industry.

Recent out-licensing deals, he said, show that Indian innovation can attract global interest if supported by the right ecosystem.

The overarching message from the panel was clear: without regulatory agility, better clinical infrastructure, stronger industry-academia links and a shift in mindset towards risk-taking and acceptance of failure, India risks ceding ground to faster-moving peers.

CKYC ID: One KEY for All Your KYC Needs



Unique 14-digit CKYC ID issued by CKYC Records Registry

HOW IT WORKS?

- Submit KYC details to your bank
- Bank uploads KYC details on Central KYC Records Registry
- Can be used across banks & financial institutions

Know your CKYC ID

- Missed call: 7799022129 or
- Official WhatsApp No. 999941355/9930919135
- Online: www.ckycindia.in

KEY BENEFITS

- 1 Open accounts easily with different banks/financial institutions
- 1 Simplifies KYC Update: KYC updated with one bank, gets updated in your all other banks/financial institutions through CKYC

Simple. Secure. Standardised.



Issued in public interest by भारतीय रिज़र्व बैंक RESERVE BANK OF INDIA www.rbi.org.in

APPOINTMENTS

Driving the delivery and growth of markets.

As a cornerstone of India's financial market infrastructure, MCX has been integral to India's economic growth, strengthening the markets through robust price discovery and effective risk management for the commodity ecosystem. Step into a leadership role that drives those markets into the future through a continued focus on innovation and governance.

LEADERSHIP OPENINGS

- EXECUTIVE DIRECTOR
Critical Operations (ED1)

Lead technology, cybersecurity, trading infrastructure and digital transformation at MCX, building future-ready market infrastructure at a national scale. Drive innovation in emerging technologies while safeguarding system resilience, reliability, integrity and regulatory compliance.

Apply at: ED1_MCX@sheffieldhaworth.com before 3 March 2026

- EXECUTIVE DIRECTOR
Regulatory, Compliance, Risk Management & Investor Grievances (ED2)

Provide enterprise-wide leadership across operational excellence, investigations, investor grievances, risk, regulatory compliance and governance. Engage closely with key stakeholders to uphold integrity, transparency and institutional credibility.

Apply at: ED2_MCX@sheffieldhaworth.com before 3 March 2026

- EXECUTIVE DIRECTOR
Business (ED3)

Lead business strategy and ecosystem relationships to increase diversity of participation and product development, liquidity enhancement and revenue diversification within a regulated market infrastructure, while maintaining strong brand positioning.

Apply at: ED3_MCX@sheffieldhaworth.com before 10 March 2026

LOCATION : MUMBAI


Multi Commodity Exchange of India Limited (MCX) is India's largest stock exchange in the commodity derivatives segment, recognised under the Securities Contracts (Regulation) Act, 1956, and regulated by SEBI as a Market Infrastructure Institution (MI).



MCX
METAL & ENERGY
Trade with Trust

CEINTECH AI Envisioning Possibilities

Ceinsys Tech delivers strong revenue growth in Q3 FY26 with consistently improving EBITDA margins



- 27 Years of Legacy
- 200+ Customers
- Global Footprint Presence across US, Europe and India
- Geospatial Services
- Technology Solutions
- Automotive Engineering

Operational and other Highlights

Confirmed Order Book as on Dec. 31, 2025: ₹999 Cr

Geospatial & Engineering Services revenue up by 76.5% YoY

Technology Solutions revenue up by 79.41% YoY

Major Milestones this Quarter

New order book during quarter: ₹170 Cr

Strategic Partnership with Tech4B & Arterisk (Singapore) - Renewed global presence of Enterprise Geospatial Programs

EXTRACT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2025

Particulars	CONSOLIDATED					
	Quarter Ended		Nine Months Ended		Year Ended	
	31.12.2025	30.09.2025	31.12.2024	31.12.2024	31.03.2025	31.03.2025
	Unaudited		Unaudited		Audited	
Total Income from Operations (Net)	169.94	163.45	111.79	489.99	275.67	418.06
Net Profit/(Loss) for the period (before Tax, Exceptional and/or Extraordinary Items)	42.07	39.55	24.18	115.48	61.13	89.54
Net Profit/(Loss) for the period before tax (after Exceptional and/or Extraordinary Items)	40.91	39.55	24.18	114.32	61.13	89.54
Net Profit/(Loss) for the period after tax (after Exceptional and/or Extraordinary Items)	38.87	25.74	17.81	96.25	41.37	63.24
Total Comprehensive Income for the period (Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income (after tax))	38.81	26.17	18.46	96.36	41.99	63.60
Paid up Equity Share Capital (Equity Share of Rs. 10/- each)	17.84	17.84	17.44	17.84	17.44	17.44
Earnings Per Share (Face Value of Rs. 10/-)						
(1) Basic (*Not Annualised):	21.79*	14.47*	10.21*	54.41*	24.70*	37.37
(2) Diluted (*Not Annualised):	19.94*	12.94*	9.95*	48.76*	24.46*	35.27

1. The above is an extract of the detailed format of statement of Unaudited Consolidated Financial Results for the quarter and nine months ended on December 31, 2025, filed with Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the said Financial Results are available on the Stock Exchange website at: www.bseindia.com and on the Company's website at: www.ceintechai.com. The same could also be accessed by scanning the QR Code provided below.

2. The Unaudited Consolidated Financial Results of Ceinsys Tech Limited (the "Company") for the quarter and nine months ended on December 31, 2025 (the "Statement") were reviewed by Audit Committee and approved by Board of Directors at their meeting held on February 9, 2026. The Statutory auditors of the Company have carried out a limited review of the above results for the quarter and nine months ended December 31, 2025.

Sd/-
Mr. Kaushik Khona
Managing Director, India Operations
DIN: 00026597

Place : Mumbai
Date : February 9, 2026
For and on behalf of Board of directors
Ceinsys Tech Limited

Registered Office : Ceinsys Tech Ltd, 10/5, IT Park, Nagpur - 440022, Maharashtra, India. CIN: L7300MH1998PLC14790
www.cestech.ai | contactus@cestech.ai | +91 712 6782800

The long road to \$500 bn

India has agreed to buy \$500 bn worth of US energy products and other goods as part of a trade deal. This won't be easy, for India has been diversifying its sources

S DINAKAR
Hyderabad, 9 February

It might be simplistic to tie the outcome of the US-India free trade agreement, which is yet to be formally signed, to India agreeing to invest \$500 billion in the US. But that's what US President Donald Trump said in a social media post last week. The joint statement issued by Washington and New Delhi on February 7 clarified that "India intends to purchase \$500 billion of US energy products, aircraft and aircraft parts, precious metals, technology products, and coking coal over the next 5 years."

That too is a tall order, especially when the document mentions energy products first. Energy products are primarily fuels such as crude oil, liquefied petroleum gas and liquefied natural gas—the gases used in the vehicles, industries and kitchens.

India imports 90 per cent of its crude oil, 60 per cent of LPG and over half of LNG. But all three energy products, which together accounted for 22 per cent of India's total imports by value in FY2025, or a combined \$175 billion, are sourced from several suppliers—primarily from West Asia and Russia. The US shipped just over \$12 billion of energy products in FY25, including coking and steam coal. Also included in this were petroleum fuels worth around \$9 billion, which made up just 5 per cent of India's total petroleum import basket by value, commerce ministry data showed—illustrating the long road ahead.

While the joint statement did not give a breakdown of the \$500 billion goal, even a 20 per cent contribution from energy products would mean India having to boost US purchases eight-fold



ILLUSTRATION: ANJANA MOHANTY

from current levels in five years—even as oil and gas prices trend lower on the back of copious supplies—according to senior officials from the public sector companies GAIL and Petro-NG Ltd. "Analysts would be wise to ignore some of the numbers in the deal, or at least treat them as aspirational," said Evan Feigenbaum, a scholar at Carnegie Endowment for International Peace, a US think tank. "But US-India trade has undershot its potential forever, so ambition is good."

Overall, India will need to boost imports of products and services from the US by over five fold in five years to meet the target, according to Feigenbaum. US goods exports to India in 2024 were around \$41.5 billion and services exports were \$4.1 billion. As for energy, the US share in India's trade basket is low in both volume and value. The US contributed 5 per cent to India's crude oil imports in volume terms in 2025, hardly 8 per cent to LNG imports and 7 per cent to LPG supplies, Kpler data showed. In value terms, purchases of US coking coal, used in steel plants, and steam coal, used as fuel, declined by 22 per cent in FY25 to \$3.2 billion compared with FY24, commerce ministry data showed. Crude purchases

Discounts reign
While it is true that India accelerated Russian crude oil imports 25-fold to over \$50 billion in FY25 from just over \$2 billion in FY22, prior to the Ukraine invasion, this surge relied on oil discounted by over \$10 per barrel, which US suppliers cannot match, senior refining officials told *Business Standard*.

Unlike buying aircraft, a market controlled by US Boeing and Europe's Airbus, petroleum is a competitive business. Indian refiners source crude oil at competitive rates from over 100 countries, said oil minister Hardeep Puri at India Energy Week (IEW) in Goa last month. LNG comes from over 100 countries, government data showed.

Because our imposed dependency is so high, to nullify the impact we constantly keep exploring different geographies," Bharat Petroleum's refining director Sanjay Khanna, who has additional charge of chairman and managing director, told *Business Standard* in an interview. "And it is part of the business plan itself that each refinery will be going for five additional (types of) crudes this year."

Newer suppliers for oil are emerging, such as Brazil and Colombia from Latin America—Brazilian supplies have jumped threefold this year from a year earlier, data from Vortexa showed. Similarly, the UAE has emerged as a big sourcing base for LNG, supplying as much as a fifth of its LNG output to India, said Adnoc Gas CEO Fatma al-Naumi. Puri added that India will import more than 4.2 million tonnes of LNG from the UAE every year under term

Tracking the trend

US exports of crude oil to India (In '000 barrels per day)

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
2015												
2017	52	51										
2018	32	20	234	17	152	348	102	196	169	218	117	195
2019	230	181	362	393	254	290	122	217	248	239	244	275
2020	220	284	182	196	265	351	200	161	279	245	435	660
2021	412	501	344	370	389	596	376	441	279	342	301	595
2022	542	353	153	217	268	215	202	95	412	460	623	205
2023	119	90	247	227	288	144	197	200	156	113	135	93
2024	96	155	254	307	301	324	260	225	199	51	231	209
2025	176	396	266	410	313	256	193	434	523	332	304	204

Source: US Energy Information Administration

US LNG exports to India (in mn tonnes)

Year	Volume
2011	0.31
2012	0.06
2013	0
2014	0
2015	0
2016	0.32
2017	0.33
2018	0.98
2019	1.77
2020	2.38
2021	3.69
2022	2.21
2023	3.13
2024	5.03
2025	2.97
2026*	0.14

Note: Figures are rounded off; *As of Feb 9 Source: Kpler

While that measured a substantial 60 per cent jump over 2024, it was still 23 per cent below the 2021 record 415,000 bpd for a 10 per cent share. Kpler data showed.

In the first 40 days of this year, Indian imports of US oil slipped 18 per cent below 2025 levels at 252,000 bpd. Meanwhile, US oil shipments to India averaged 180,000 bpd in December 2025 and January 2026 compared with \$20,000 bpd in September 2025.

US LNG, which is Trump's biggest

pitch to foreign nations, represented just 12 per cent, or 2.9 million tonnes, of India's total imports in 2025, down from a 19 per cent share in 2024 despite GAIL India boosting its fleet capacity, according to Kpler.

A jump in the price of US benchmark natural gas index Henry Hub (HH) this winter over \$50 per million British thermal units (MMBtu) from \$4 million Btu earlier has caused concern among India's LNG importers, especially GAIL, which has long-term contracts for 5.8 million tonnes of US LNG, senior company officials said.

The US shipped 319,000 bpd of crude oil in calendar 2025 to take a 6.5 per cent share of India's crude import market. While spikes are normal in

winter, these rates are unacceptable to Indian consumers.

Until last year, there was a rush for HH-linked contracts, said a senior LNG trader at a state oil company. The situation has reversed after HH gained strength in the last few months, the trader said. Indian state-run oil companies had signed up for around 10 million tons per year of LNG in the December 2024-April 2025 period in HH-linked deals.

The spike in HH rates—which the US Energy Information Administration expects to harden this year and the next—has led Indian LNG importers to review US proposals for LNG supplies, industry officials said and data showed.

Petronet LNG managing director Akshay Kumar Singh and Sandeep Kumar Gupta, chairman, GAIL, emphasised at IEW that LNG prices must be affordable—below \$9 per million Btu—for Indian purchases to surge. At \$60 per barrel oil levels, India can bring in LNG at around \$8 per million Btu but delivering LNG from the US at even \$4 per million Btu HH costs over \$10 per million Btu, industry officials said.

LPG supplies to India are primarily driven by imports from West Asia, TV Pandian, Business Head (LPG), Bharat Petroleum said. The first term-contract for US LPG, expected to account for 10 per cent of India's LPG imports, will start soon, he said.

But given the proximity of Gulf nations to India, long-haul voyages from the US may be one cross too many to bear for India, a country with a voracious appetite for energy products.

PALASH SECURITIES LIMITED
REGD. OFFICE: P-0, HARGANJ, DIST. SITAPUR (U.P.), PIN - 201 121
Phone No. (0566) 2522021; Fax No. (0566) 255 225
E-mail: palashsecurities@rediffmail.com Website: www.palashsg.com

NOTICE TO SHAREHOLDERS
Special Window for Transfer and Dematerialisation of Physical Securities Pursuant to SEBI Circular No. HD/28/13/17, 2022-MRSD-POD/1575/2026 dated January 30, 2026, a Special Window has been opened from February 05, 2026 to February 04, 2027, to facilitate transfer and dematerialisation of physical securities which were sold/purchased prior to April 01, 2019. The Special Window is also available for such transfer requests which were lodged prior to April 1, 2019 and were rejected/returned/unattended due to deficiency in the document/process/other reasons. During this period, the securities that are re-logged for transfer (including those requests that are pending with the listed company/RTA, as on date) shall be issued only in demat mode. However, due process shall be followed for such transfer-cum-demat requests. Shareholders who wish to avail the opportunity are requested to submit the original security certificate(s), transfer deed and all other documents in the Circular to the Company's Registrar and Transfer Agent, i.e., MUFG India Private Limited at Raspi Court, 5th Floor, 20, Sir R. N. Mukherjee Road, Kolkata 700011, India (Unit: Palash Securities Limited) to enable further processing and transfer of shares, in accordance with the applicable laws.

For Palash Securities Limited
Sd/-
Vijay Kumar Mishra
Company Secretary
FCS - 11269

Place: Kolkata
Date: February 09, 2026

JM FINANCIAL LIMITED
Corporate Identity Number: L67120M1998PLC03874
Registered Office: 7th Floor, Energy, Appasahab Maharaj, Panchsahi, Mumbai 400 022
Tel. No.: +91 22 6930 3030 • Fax: +91 22 6930 3223
Website: www.jmfinl.com • Email: com@jmfinl.com

NOTICE TO SHAREHOLDERS
SPECIAL WINDOW FOR REDEMPTION OF TRANSFER REQUESTS OF EQUITY SHARES HELD IN PHYSICAL MODE
JM Financial Limited hereby informs its shareholders that the Securities and Exchange Board of India vide its Circular dated January 30, 2026, has approved reopening of special window for redemption of transfer requests of equity shares held in physical mode. To facilitate ease of investing and safeguard the rights of investors in respect of the securities purchased by them, this special window has been opened solely for the redemption of physical transfer deeds that were originally executed prior to April 1, 2019.

This special window will remain open until February 4, 2027, providing shareholders with one year to re-logic their physical transfer requests.

For better understanding of the aforesaid Circular, please refer to the matrix given below.

Execution date of transfer deed	Lodged for transfer before April 1, 2019?	Original Share Certificate available?	Eligible to lodge in the current window?
No (it is fresh lodgement)	Yes	Yes	Yes
Before April 01, 2019	Yes (it was rejected/ returned earlier)	Yes	Yes
	Yes	No	No
	No	No	No

Eligible shareholders are requested to refer the Circular for further details and re-logic physical shares for transfer during the special window period to the Company's Registrar and Transfer Agent, KPN Technologies Limited, Unit: JM Financial Limited, Solenium Building, Tower-2, Plot No. 31 & 32, Financial District, Nanaravandraya, Seelapangam, Hyderabad, Rangareddy, Telangana - 500032. Email: einward@jmfinl.com, to avail the benefit of this facility.

For JM Financial Limited
Date: February 9, 2026
Place: Mumbai
Hemant Pandya
Company Secretary & Compliance Officer

पंजाब नॅशनल बँक Punjab National Bank
CENTRALISED PROCUREMENT & PARTNERSHIP DIVISION
H-2, 5, SANDAN MARG, NEW DELHI-110001
(Email ID: cpdp.processing@pnb.co.in, Phone: 011-23742596
Date: 09.02.2026

TENDER NOTICE
Punjab National Bank invites online bids (both technical and commercial) from eligible bidders for "Request for Proposal (RFP) for Procurement of End-to-End Data Classification Solution," through GeM Portal (Government e Marketplace). Interested bidders may visit website <https://gem.gov.in/> for details.
BID No: GEM/2026/B/17207133
Bid floated on GeM Portal dated 07.02.2026
Prebid Meeting date: 17.02.2026
The last date for online bid submission is 07.03.2026 at 16:00 hrs. Chief Manager

Patel Retail Limited
CIN No: L52100M1200PLC11625
Registered Address: Plot No. 40, Grand Nagpur Industrial MIDC, Ambernath (East), Thane, Mumbai, Maharashtra, India, 421506, Tel: 0251 2691991/2628400, Tel. No.: +91 22 6930 3030 • Fax: +91 22 6930 3223
Website: www.patelrtd.com • Email: com@patelrtd.com

NOTICE OF POSTAL BALLOT
Shareholders are hereby informed that Pursuant to Sections 110 & 108 of the Companies Act, 2013, Companies Management & Administration Rules, 2011 General Circular No. 14/2020 dated April 08, 2020 & General Circular No. 17/2020 dated April 03, 2020 read with other relevant notices, issued by the Ministry of Corporate Affairs & Regulation 44 of the SEBI Listing Obligations & Disclosure Requirements (Regulations, 2015, and any other applicable provisions if any, the Company has, through M/s Bigshare Services Private Limited, sent Notice of Postal Ballot vide e-mail dated Monday, February 09, 2026 only to all shareholders who have registered their e-mail IDs with the Depository Participant(s) being the cut-off date on Friday, February 06, 2026, together with an Explanatory Statement pursuant to Section 102 of the Act, along with the Log ID & password, for seeking their approval on the following resolutions:

Sr.	Description	Type of Resolution
1	Continuation of Mr. Bechar Raghavi Patel (DIN: 02109626) as Whole-time Director of the Company beyond the age of 70 Years.	Special Resolution
2	Appointment of M/s Deep Shukla & Associates as Secretarial Auditor of the Company for a term of 5 years.	Ordinary Resolution
3	Approval to give loans, inter-company deposits, provide guarantees, and other financial assistance exceeding the limits prescribed under Section 186 of the Companies Act, 2013.	Special Resolution

The Board of Directors of the Company has appointed M/s Deep Shukla & Associates Practicing Company Secretary, to act as the Scrutinizer, for conducting the Postal Ballot process, in a fair & transparent manner. The communication of the result of the Postal Ballot will be done through the e-voting system only.

The Company has appointed Bigshare Services Private Limited for facilitating e-voting by the Members. The detailed procedure for e-voting is as follows in the Notes to the Postal Ballot Notice, the e-voting period is as follows:

VOTING START ON	VOTING ENDS ON
Tuesday, February 10, 2026 at 09:00 AM (IST)	Wednesday, March 11, 2026 AT 05:00 PM (IST)

Members are requested to note that voting beyond Wednesday, March 11, 2026 AT 05:00 PM (IST) will not be allowed & the e-voting module shall be disabled thereafter. A person who is not a Member of the Company as on the cut-off date should treat the Notice of Postal Ballot for information purpose only.

The copy of the Postal Ballot Notice will be available on the Company's website at <https://patelrtd.com/investor-relations>, website of the Stock Exchange (i.e. BSE Limited) at <https://www.bseindia.com> & National Stock Exchange of India Limited & <https://www.nseindia.com>, respectively. Members who do not receive the Postal Ballot Notice may download it from above-mentioned websites.

In case shareholders/investor have any queries regarding e-voting, you may refer the Frequently Asked Questions (FAQs) & e-voting module available at <https://investor.patelrtd.com>, under download section or you can email us to invest@patelrtd.com or call us at: 022-26283336. The result of the e-voting by Postal Ballot will be announced on or before Friday, March 13, 2026 at the Registered Office of the Company & shall be available at the above said Company's website.

For Patel Retail Limited
Sd/-
Prasad Ramesh Khanna
Company Secretary

Monday, February 09, 2026
Ambernath, Thane, Mumbai

CS TECH AI
Enabling Possibilities

Ceinys Tech delivers strong revenue growth in Q3 FY26 with consistently improving EBITDA margins

Quarterly Revenue (INR Cr)	YoY Growth	EBITDA Margins (%)
Q1 FY25: 73.8	17.92%	17.92%
Q2 FY25: 90.0	18.6%	18.6%
Q3 FY25: 111.8	19.0%	19.0%
Q4 FY25: 142.4	18.80%	18.80%
Q1 FY26: 156.6	19.32%	19.32%
Q2 FY26: 163.5	21.79%	21.79%
Q3 FY26: 169.9	23.48%	23.48%

Q3 FY26 Revenue: ₹169.94 Cr (YoY +23.48%)
Q3 FY26 EBITDA: ₹39.91 Cr (YoY +88%)
Q3 FY26 PAT: ₹38.87 Cr (YoY +118%)

Operational and other Highlights
Confirmed Order Book as on Dec. 31, 2025: ₹999 Cr
Geospatial & Engineering Services revenue up by 76.5% YoY
Technology Solutions revenue up by 79.41% YoY

Major Milestones this Quarter
New order book surging over ₹170 Cr
Strategic Partnership with Tech M&A Advisory (Singapore) to support global Enterprise Geospatial Programs

EXTRACT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2025

CONSOLIDATED (in Rs. Cr)

Particulars	Quarter Ended		Nine Months Ended		Year Ended
	31.12.2025	30.09.2025	31.12.2024	31.12.2024	
Total Income from Operations (Net)	169.94	163.45	111.79	489.99	418.06
Net Profit/(Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	42.07	39.55	24.18	115.48	89.54
Net Profit/(Loss) for the period before tax (after Exceptional and/or Extraordinary items)	40.91	39.55	24.18	114.32	89.54
Net Profit/(Loss) for the period after tax (after Exceptional and/or Extraordinary items)	38.87	25.74	17.81	96.25	63.24
Total Comprehensive Income for the period comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income (after tax)	38.81	26.17	18.46	96.36	63.60
Paid up Equity Share Capital (Equity Share of Rs. 10/-each)	17.84	17.84	17.44	17.84	17.44
Earnings Per Share (Face Value of Rs. 10/-)					
1) Basic (*Not Annualised):	21.79*	14.47*	10.21*	54.41*	24.70*
2) Diluted (*Not Annualised):	19.94*	12.94*	9.95*	48.76*	24.46*

1. The above is an extract of the detailed format of statement of Unaudited Consolidated Financial Results for the quarter and nine months ended on December 31, 2025, filed with Stock Exchanges under Section 31 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the said financial results are available on the Company website at: [www.ceinystech.com](https://ceinystech.com) and on the Company's website at: www.ceinystech.com. The same could also be accessed by scanning the QR Code provided below.

2. The Unaudited Consolidated Financial Results of Ceinys Tech Limited the "Company" for the quarter and nine months ended on December 31, 2025 (the "Statement") were reviewed by Audit Committee and approved by Board of Directors at their meeting held on February 9, 2026. The Statutory auditors of the Company have carried out a limited review of the above results for the quarter and nine months ended December 31, 2025.

Sd/-
M. Kaushik Khanna
Managing Director, Ceinys Operations
DIN: 72300MH1998PLC114790
CIN: 09262597

Place: Mumbai
Date: February 9, 2026
For and on behalf of Board of directors
Ceinys Tech Limited

Registered Office: Ceinys Tech Ltd, 10/5, IT Park, Nagpur - 440022, Maharashtra, India. (DIN: 72300MH1998PLC114790)
www.ceinystech.ai | contactus@ceinystech.ai | +91 712 6782800

The long road to \$500 bn

India has agreed to buy \$500 bn worth of US energy products and other goods as part of a trade deal. This won't be easy, for India has been diversifying its sources

S DINAKAR
Hyderabad, 9 February

It might be simplistic to tie the outcome of the US-India free trade agreement, which is yet to be formally signed, to India agreeing to invest \$500 billion in the US. But that's what US President Donald Trump said in a social media post last week. The joint statement issued by Washington and New Delhi on February 7 clarified that "India intends to purchase \$500 billion of US energy products, aircraft and aircraft parts, precious metals, technology products, and coking coal over the next 5 years."

That too is a tall order, especially when the document mentions energy products first. Energy products are primarily fuels such as crude oil, liquefied petroleum gas and liquefied natural gas—the gases used in the vehicles, industries and kitchens.

India imports 90 per cent of its crude oil, 60 per cent of LPG and over half of LNG. But all three energy products, which together accounted for 22 per cent of India's total imports by value in FY2024, or a combined \$175 billion, are sourced from several suppliers—primarily from West Asia and Russia. The US shipped just over \$12 billion of energy products in FY25, including coking and steam coal. Also included in this were petroleum fuels worth around \$9 billion, which made up just 5 per cent of India's total petroleum import basket by value, commerce ministry data showed—illustrating the long road ahead.

While the joint statement did not give a breakdown of the \$500 billion goal, even a 20 per cent contribution from energy products would mean India having to boost US purchases eight-fold




ILLUSTRATION: ANJANA MOHANTY

from current levels in five years—even as oil and gas prices trend lower on the back of copious supplies—according to senior officials from the public sector companies GAIL and Petro-NG Ltd.

"Analysts would be wise to ignore some of the numbers in the deal, or at least treat them as aspirational," said Evan Feigenbaum, a scholar at Carnegie Endowment for International Peace, a US think tank. "But US-India trade has undershot its potential forever, so ambition is good."

Overall, India will need to boost imports of products and services from the US by over five fold in five years to meet the

target, according to Feigenbaum. US goods exports to India in 2024 were around \$41.5 billion and services exports were \$4.1 billion. As for energy, the US share in India's trade basket is low in both volume and value. The US contributed 5 per cent to India's crude oil imports in volume terms in 2025, hardly 8 per cent to LNG imports and 7 per cent to LPG supplies, Kpler data showed.

In value terms, purchases of US coking coal, used in steel plants, and steam coal, used as fuel, declined by 22 per cent in FY25 to \$3.2 billion compared with FY24, commerce ministry data showed. Crude purchases

at competitive rates from over 25-fold to over \$50 billion in FY25, prior to the Ukraine invasion, this surge led to oil discounted by over \$10 per barrel, which US suppliers cannot match, senior refining officials told *Business Standard*.

Unlike buying aircraft, a market controlled by US Boeing and Europe's Airbus, petroleum is a competitive business. Indian refiners source crude oil from the US, said oil minister Hardeep Puri at India Energy Week (IEW) in Goa last month. LNG comes from over 10 countries, government data showed.

Because our imposed dependency is so high, to nullify the impact we constantly keep exploring different geographies," Bharat Petroleum's refining director Sanjay Khanna, who has additional charge of chairman and managing director, told *Business Standard* in an interview. "And it is part of the business plan itself that each refinery will be going for five additional (types of) crudes this year."

Newer suppliers for oil are emerging, such as Brazil and Colombia from Latin America—Brazilian supplies have jumped threefold this year from a year earlier, data from Vortexa showed. Similarly, the UAE has emerged as a big sourcing base for LNG, supplying as much as a fifth of its LNG output to India, said Adnoc Gas CEO Fatma al-Naumi. Puri added that India will import more than 4.2 million tonnes of LNG from the UAE every year under term

Tracking the trend

US exports of crude oil to India (In '000 barrels per day)

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
2015												
2017		52	10	51								
2018	32	20	234	17	152	348	102	196	169	218	117	195
2019	230	181	362	393	254	290	122	217	248	239	244	275
2020	220	284	182	196	265	351	200	161	276	245	435	660
2021	412	501	344	370	389	596	376	441	479	342	603	595
2022	542	353	153	217	268	215	202	95	412	460	623	205
2023	119	90	247	227	288	144	197	200	156	113	135	93
2024	96	155	254	307	301	324	260	225	199	321	231	209
2025	176	396	266	410	313	256	193	434	523	332	304	N/A

Source: US Energy Information Administration

US LNG exports to India (in mn tonnes)

Year	Volume
2011	0.31
2012	0.06
2013	0
2014	0
2015	0
2016	0.32
2017	0.33
2018	0.98
2019	1.77
2020	2.38
2021	3.69
2022	2.21
2023	3.13
2024	5.03
2025	2.97
2026*	0.14

Note: Figures are rounded off; *As of Feb 9 Source: Kpler

contracts—half as much as it imports from Qatar now. French major Total has resumed work at Mozambique LNG, where Indian state oil companies hold a 30 per cent stake and which is a much shorter journey than the US. Oil India CEO Ranjit Rath said the company is participating in the buildout of the \$20 billion Mozambique LNG project to provide Indian consumers a cheaper, reliable source of LNG.

Canadian energy minister Tim Hodgson, a key guest at IEW, expressed strong interest in deepening cooperation with India, particularly in the areas of LNG, oil supplies and long-term energy trade.

No hurry The availability of alternative sources of both oil and LNG has tempered the enthusiasm for US fuels, a senior oil trader said. The trader also said that state-run oil companies, the biggest importers of energy, are bound by strict oversight and sourcing rules that bar preferential treatment for any importing nation, unless there is an explicitly declared formal mandate.

The US shipped 319,000 bpd of crude oil in calendar 2025 to take a 6.5 per cent share of India's crude import market.

While that measured a substantial 60 per cent jump over 2024, it was still 23 per cent below the 2021 record 415,000 bpd for a 10 per cent share. Kpler data showed.

In the first 40 days of this year, Indian imports of US oil slipped 18 per cent below 2025 levels at 252,000 bpd. Meanwhile, US oil shipments to India averaged 180,000 bpd in December 2024 and January 2025 compared with \$20,000 bpd in September 2025.

US LNG, which is Trump's biggest pitch to foreign nations, represented just 12 per cent, or 2.9 million tonnes, of India's total imports in 2025, down from a 19 per cent share in 2024 despite GAIL India boosting its fleet capacity, according to Kpler.

A jump in the price of US benchmark natural gas index Henry Hub (HH) this winter over \$50 per million British thermal units (MMBtu) from \$4 million Btu earlier has caused concern among India's LNG importers, especially GAIL, which has long-term contracts for 5.8 million tonnes of US LNG, senior company officials said.

A top GAIL official said that while spikes are normal in winter, these rates are unacceptable to Indian consumers. Until last year, there was a rush for HH-linked contracts, said a senior LNG trader at a state oil company. The situation has reversed after HH gained strength in the last few months, the trader said. Indian state-run oil companies had signed up for around 10 million tons per year of LNG in the December 2024-April 2025 period in HH-linked deals.

The spike in HH rates—which the US Energy Information Administration expects to harden this year and the next—has led Indian LNG importers to review US proposals for LNG supplies, industry officials said and data showed.

Petronet LNG managing director Akshay Kumar Singh and Sandeep Kumar Gupta, chairman, GAIL, emphasised at IEW that LNG prices must be affordable—below \$9 per million Btu—for Indian purchases to surge. At \$60 per barrel oil levels, India can bring in LNG at around \$8 per million Btu but delivering LNG from the US at even \$4 per million Btu HH costs over \$10 per million Btu, industry officials said.

LPG supplies to India are primarily driven by imports from West Asia, TV Pandeyan, Business Head (LPG), Bharat Petroleum said. The first term-contract for US LPG, expected to account for 10 per cent of India's LPG imports, will start soon, he said.

But given the proximity of Gulf nations to India, long-haul voyages from the US may be one cross too many to bear for India, a country with a voracious appetite for energy products.

PALASH SECURITIES LIMITED
REGD. OFFICE: P-0, HARGAON, DIST. SITAPUR (U.P.), PIN - 201 121
Phone No. : (0562) 2522021; Fax No. : (0562) 255 225
E-mail: palashsecurities@rediffmail.com Website: www.palashsecurities.com

NOTICE TO SHAREHOLDERS
Special Window for Transfer and Dematerialisation of Physical Securities Pursuant to SEBI Circular No. HD/38/13/17, 2022-MRSD-POD/1575/2026 dated January 30, 2023, a Special Window has been opened from February 05, 2024 to February 04, 2027, to facilitate transfer and dematerialisation of physical securities which were sold/purchased prior to April 01, 2019. The Special Window is also available for such transfer requests which were lodged prior to April 1, 2019 and were rejected/returned/unattended due to deficiency in the documentation process or otherwise. During this period, the securities that are re-logged for transfer (including those requests that are pending with the listed company/RTA, as on date) shall be issued only in demat mode. However, due process shall be followed for such transfer-cum-demat requests. Shareholders who wish to avail the opportunity are requested to submit the original security certificate(s), transfer deed and all other documents listed in the Circular to the Company's Registrar and Transfer Agent, i.e., MUFG India Private Limited at Raspi Court, 5th Floor, 20, Sir R. N. Mukherjee Road, Kolkata 700011, India (Unit: Palash Securities Limited) to enable further processing and transfer of shares, in compliance with the applicable laws.

For Palash Securities Limited
Sd/-
Vijay Kumar Mishra
Company Secretary
FCS - 11269

Place: Kolkata
Date: February 09, 2026

JM FINANCIAL LIMITED
Corporate Identity Number: L67120M11969P103874
Registered Office: 7th Floor, Equinox, Appasaheb Marathe Marg, Prabhadevi, Mumbai 400 026
Tel. No.: +91 22 6930 3030 • Fax: +91 22 6930 3223
Website: www.jmfin.com • Email: com@jmfin.com

NOTICE TO SHAREHOLDERS
SPECIAL WINDOW FOR REDEMPTION OF TRANSFER REQUESTS OF EQUITY SHARES HELD IN PHYSICAL MODE

JM Financial Limited hereby informs its shareholders that the Securities and Exchange Board of India vide its Circular dated January 30, 2026, has announced opening of special window for redemption of transfer requests of equity shares held in physical mode.

To facilitate ease of investing and safeguard the rights of investors in respect of the securities purchased by them, this special window will be opened solely for the redemption of physical transfer deeds that were originally executed prior to April 1, 2019.

This special window will remain open until February 4, 2027, providing shareholders with one year to re-logic their physical transfer requests.

For better understanding of the aforesaid Circular, please refer to the matrix given below.

Execution date of transfer deed	Lodged for transfer before April 1, 2019?	Original Share Certificate available?	Eligible to lodge in the special window?
No (i.e. is fresh lodgement)	Yes	Yes	Yes
Before April 01, 2019	Yes (i.e. was rejected/ returned earlier)	Yes	Yes
	Yes	No	No
	No	No	No

Eligible shareholders are requested to refer the Circular for further details and re-logic physical shares for transfer during the special window period to the Company's Registrar and Transfer Agent, KPN Technologies Limited, Unit: JM Financial Limited, Solenium Building, Tower-2, Plot No. 31 & 32, Financial District, Nanaknagar, Serlingampally, Hyderabad, Rangareddy, Telangana - 500032, Email: einward@se@jmfin.com, to avail the benefit of this facility.

For JM Financial Limited
Date: February 9, 2026
Place: Mumbai
Hemant Pandya
Company Secretary & Compliance Officer

पंजाब नॅशनल बँक Punjab National Bank
CENTRALISED PROCUREMENT & PARTNERSHIP DIVISION
H-2, 5, SANDAN MARG, NEW DELHI-110001
(Email ID: cpdp_processing@pnb.co.in, Phone: 011-23724596)
Date: 09.02.2026

TENDER NOTICE
Punjab National Bank invites online bids (both technical and commercial) from eligible bidders for "Request for Proposal (RFP) for Procurement of End-to-End Data Classification Solution," through GeM Portal (Government e Marketplace). Interested bidders may visit website <https://gem.gov.in/> for details.

BID No: GEM/2026/B/17207133
Bid floated on GeM Portal dated 07.02.2026
Prebid Meeting date: 17.02.2026
The last date for online bid submission is 07.03.2026 at 16:00 hrs.
Chief Manager

Patel Retail Limited
CIN No: L52100M1200PLC11625
Registered Address: Plot No. 102, Grand Nagpada Industrial MIDC, Ambernath (East), Thane, Mumbai, Maharashtra, India, 421506, Tel: 0251 262199/2628400.
Tel. No.: info@patelrnl.com | www.patelrnl.com

NOTICE OF POSTAL BALLOT
Shareholders are hereby informed that Pursuant to Sections 110 & 108 of the Companies Act, 2013, Companies Management & Administration Rules, 2011 General Circular No. 14/2020 dated April 08, 2020 & General Circular No. 17/2020 dated April 03, 2020 read with other relevant notices, issued by SEBI, the Board of Directors of the Company has appointed Mrs. Deep Shikha & Associates Practicing Company Secretary, to act as the Scrutinizer for conducting the Postal Ballot process, in a fair & transparent manner. The communication of the consent or dissent of the Members would take place through the e-voting system only.

The Company has appointed Bigshare Services Private Limited for facilitating e-voting by the Members. The detailed procedure for e-voting is as follows:-

VOTING START ON Tuesday, February 10, 2026 at 09:00 AM (IST)
VOTING ENDS ON Wednesday, March 11, 2026 AT 05:00 PM (IST)

Members are requested to note that voting beyond Wednesday, March 11, 2026 AT 05:00 PM (IST) will not be allowed & the e-voting module shall be disabled thereafter. A person who is not a Member of the Company as on the 'cut-off date' should treat the Notice of Postal Ballot for information purpose only.

The copy of the Postal Ballot Notice will be available on the Company's website at <https://patelrnl.com> and the website of the Stock Exchange (i.e. BSE Limited at <https://www.bseindia.com> and National Stock Exchange of India Limited at <https://www.nseindia.com> respectively. Members who do not receive the Postal Ballot Notice may download it from above-mentioned websites.

In case shareholders/investor have any queries regarding e-voting, you may refer the Frequently Asked Questions (FAQs) & e-voting module available at <https://www.patelrnl.com>, under download section or you can email us to investor@patelrnl.com or call us at: 022-26283336. The result of the e-voting by Postal Ballot will be announced on or before Friday, March 13, 2026 at the Registered Office of the Company & shall be available on the above said Company's website.

For Patel Retail Limited
Sd/-
Prasad Ramesh Khokhar
Company Secretary

CSTECHAI
Enabling Possibilities

Geospatial Tech delivers strong revenue growth in Q3 FY26 with consistently improving EBITDA margins

Quarterly Revenue (INR Cr)	YoY Growth	EBITDA Margins (%)
Q1 FY25: 73.8	17.92%	17.92%
Q2 FY25: 90.0	18.6%	18.80%
Q3 FY25: 111.8	19.0%	19.32%
Q4 FY25: 142.4	19.2%	21.79%
Q1 FY26: 156.6	19.3%	23.48%
Q2 FY26: 163.5	18.6%	18.80%
Q3 FY26: 169.9	19.0%	19.32%

Q3 FY26 Revenue: ₹169.9 Cr (YoY +19.0%)
Q3 FY26 EBITDA: ₹39.91 Cr (YoY +88%)
Q3 FY26 PAT: ₹38.87 Cr (YoY +118%)

Operational and other Highlights: Confirmed Order Book as on Dec. 31, 2025 ₹999 Cr
Geospatial & Engineering Services revenue up by 76.5% YoY
Technology Solutions revenue up by 79.41% YoY

Major Milestones this Quarter: New order book surging over ₹170 Cr
Strategic Partnership with Tech M8 Agency (Singapore) for providing global Enterprise Geospatial Solutions

EXTRACT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2025

Particulars	CONSOLIDATED					
	Quarter Ended		Nine Months Ended		Year Ended	
	31.12.2025	30.09.2025	31.12.2024	31.12.2024	31.12.2024	31.03.2025
Total Income from Operations (Net)	169.94	163.45	111.79	489.99	275.67	418.06
Net Profit/(Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	42.07	39.55	24.18	115.48	61.13	89.54
Net Profit/(Loss) for the period before tax (after Exceptional and/or Extraordinary items)	40.91	39.55	24.18	114.32	61.13	89.54
Net Profit/(Loss) for the period after tax (after Exceptional and/or Extraordinary items)	38.87	25.74	17.81	96.25	41.37	63.24
Total Comprehensive Income for the period comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income (after tax)	38.81	26.17	18.46	96.36	41.99	63.60
Paid up Equity Share Capital (Equity Share of Rs. 10/-each)	17.84	17.84	17.44	17.84	17.44	17.44
Earnings Per Share (Face Value of Rs. 10/-)						
(1) Basic (*Not Annualised):	21.79*	14.47*	10.21*	54.41*	24.70*	37.37
(2) Diluted (*Not Annualised):	19.94*	12.94*	9.95*	48.76*	24.46*	35.27

1. The above is an extract of the detailed format of statement of Unaudited Consolidated Financial Results for the quarter and nine months ended on December 31, 2025, filed with Stock Exchange under Section 31 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015. The full format of the said Financial Results are available on the Company website at: www.geospatial.com and on the Company's website at: www.cstechnai.com. The same results shall be audited by members of the QR Circle provided below.

2. The Unaudited Consolidated Financial Results of Geospatial Tech Limited the "Company" for the quarter and nine months ended on December 31, 2025 (the "Statement") were reviewed by Audit Committee and approved by Board of Directors at their meeting held on February 9, 2026. The Statutory auditors of the Company have carried out a limited review of the above results for the quarter and nine months ended on December 31, 2025.

Sd/-
M. Kaushik Khona
Managing Director, India Operations
CIN: L72300MH1998PL114790
DIN: 00526597

Place: Mumbai
Date: February 9, 2026
For and on behalf of Board of directors
Geospatial Tech Limited

Registered Office: Ceinays Tech Ltd, 10/5, IT Park, Nagpur - 440022, Maharashtra, India. | www.cstechnai.com | contactus@cstechnai.com | +91 712 6782800

CSTech
CEINSYS TECH LIMITED
 Reg. Office: 10/5, IT Park, Nagpur - 440022
 Corporate Identification Number (CIN) : L72300MH1998PLC114790
 Td No. : 91 712 6782800, Web: www.cstech.ai, Email: cs@cstech.ai

EXTRACT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2025

Particulars	CONSOLIDATED					
	Quarter Ended		Nine Months Ended		Year Ended	
	31.12.2025	30.09.2025	31.12.2024	31.12.2024	31.12.2024	31.03.2025
	Unaudited		Unaudited		Audited	
Total Income from Operations (Net)	169.94	163.45	111.79	489.99	275.67	418.06
Net Profit / (Loss) for the period before tax (Exceptional and/or Extraordinary Items)	42.07	39.55	24.18	115.48	61.13	89.54
Net Profit/(Loss) for the period before tax (after Exceptional and/or Extraordinary Items)	40.91	39.55	24.18	114.32	61.13	89.54
Net Profit/(Loss) for the period after tax (after Exceptional and/or Extraordinary Items)	38.87	25.74	17.81	96.25	41.37	63.24
Total Comprehensive Income for the period (Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income (after tax))	38.81	26.17	18.46	96.36	41.99	63.60
Paid up Equity Share Capital (Equity Share of Rs. 10/- each)	17.84	17.84	17.44	17.84	17.44	17.44
Earnings Per Share (Face Value of Rs. 10/-)	21.79*	14.47*	10.21*	54.41*	24.70*	37.37
(1) Basic (*Not Annualised); (2) Diluted (*Not Annualised);	19.94*	12.94*	9.95*	48.78*	24.46*	35.27

NOTES

1. The above is an extract of the detailed format of statement of Unaudited Consolidated Financial Results for the quarter and nine months ended on December 31, 2025, filed with Stock Exchanges under Regulation 35 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the said Financial Results are available on the Stock Exchange website at: www.bseindia.com and on the Company's website at: www.cstech.ai. The same could also be accessed by scanning the QR Code provided below.

2. The Unaudited Consolidated Financial Results of Ceinsys Tech Limited for the quarter and nine months ended on December 31, 2025 (the "Statement") were reviewed by Audit Committee and approved by Board of Directors at their meeting held on February 9, 2026. The Statutory auditors of the Company has carried out a limited review of the above results for the quarter and nine months ended December 31, 2025.

For and on behalf of Board of directors
 Ceinsys Tech Limited
 Mr. Kaushik Sharma
 Managing Director, India Operations
 DIN: 00025597

Place : Mumbai
 Date : February 9, 2026

Bandhan Bank
 Regional Office: Netaji Marg, N. Mithakhali Six Roads, Ellisbridge, Ahmedabad-6. Phone: + 91-79-26421671-75

Demanded Notice to Borrowers

The under mentioned account turned into N.P.A and demand notice issued by Bandhan Bank Ltd to the following borrower(s), under sec.13(2) of the Securitization and Reconstruction of Financial Assets and Enforcement of Security Interest Act (The Act), 2002 which was returned unsecured. Hence, this notice is issued to you all and public at large through publication.

Name of borrower(s) and Loan Account No.	Description of mortgaged property (Secured Asset)	Date of Demand Notice/Due of NPA	D/S Amount as on Date of Demand Notice	Date of Posting of Notice
Abhinav Ashwin Kulkarni Ashwin Bankim Kulkarni Chandana Ashwin Kulkarni 2000510000141	All Piece And Parcel Of Immovable Property Situated At P. H. No. 74, 5th Street, Survey No. 148, Plot No. 65, Westside portion, The Unique Co-operative Housing Society Ltd, Mouza- Bokhorda, Within limits of Grampanchayat Bhehi, Talash-Nagpur (Jurat), Dist- Nagpur, Maharashtra- 441108. Area admeasuring about 93.74 Sq Mtrs and 48.87 Sq. Mtrs. Construction area as per 7/12. And bounded by North: Plot No. 66, East: Remaining portion of Plot No. 65, West: Road, South: Undivided Share/Portion of Plot No. 65.	December 12, 2025/ November 03, 2025	Rs. 9,89,009.38	January 29, 2026
Rajesh Manoharao Hatwar Rajesh Manoharao Hatwar Asha Rajesh Hatwar 2000500000884 2000500000885	All Piece And Parcel Of Immovable Property Situated At Plot No. 1, 2, 7 and 8 out of Gat No. 130(4), Tashri Saza No. 12, Flat No. 101 and 102, First Floor Building known and titled as Excel Infra, Mouza- Khudoli, Talash and Dist- Bundlary, Maharashtra-441906. Area admeasuring about 56.01+56.01+112.02 Sq. Mtr. Builtup area. And bounded as under: North: As per plan, East: As per plan, West: As per plan, South: As per plan.	November 15, 2025/ May 06, 2025	Rs. 24,51,430.41	January 28, 2026

Demand made against you through this notice to repay to the Bank dues mentioned against your name with interest, costs and charges within 60 days from the date hereof, failing which the Bank will further proceed to take legal steps as per Sec.13(2) of the SARFAESI Act. The borrower's/mortgagor's attention is invited to the provision of sub-section (8) of section 13 of the Act, in respect of time available, to redeem the secured assets.

Place: Nagpur
 Date: February 10, 2026

Authorized Officer
 Bandhan Bank Limited

JANA SMALL FINANCE BANK
 (A Scheduled Commercial Bank)

Registered Office: The Fairway, Ground & First Floor, Survey No. 10/1, 11/2 & 12/2B, Off Donjur, Koramangla Inner Ring Road, Near to EGL Business Park, Challaghatta, Bangalore-560071. Branch Office: 101 & 102, Ground Floor, Perfect Plaza (Prasadam), Plot No.97, Cement Road, Telegraph Colony, Pratap Nagar, Nagpur (MH)-440022.

E-AUCTION NOTICE

PUBLIC NOTICE FOR SALE THROUGH E-AUCTION UNDER THE SECURITIZATION AND RECONSTRUCTION OF FINANCIAL ASSETS AND ENFORCEMENT OF SECURITY INTEREST ACT (SARFAESI ACT) 2002, READ WITH PROVISIONS RULE 8(i) & (j) OF SECURITY INTEREST (ENFORCEMENT) RULES 2002

The undersigned as authorized officer of Jana Small Finance Bank Limited has taken possession of the following property in exercise of powers conferred under section 13(4) of the SARFAESI Act. The Borrower in possession and public at large are informed that the auction (possession) of the mortgaged property in the below mentioned auction for realization of dues of the Bank will be held on "AS IS WHERE IS BASIS" and "AS IS WHAT IS BASIS" on the date as prescribed as here under:

Sr. No.	Loan Account Number	Name of Original Borrower/Co-Borrower/Guarantor	Date of 13-2 Notice	Date of Possession	Present Outstanding balance as on	Date & Time of Inspection of the property	Reserve Price	Earnest Money Deposit (EMD) in INR	Date and Time of Auction	Last Date & Place for submission of Bid
1	51779430000120	1) Mr. Swapnil Sushakar Barve, 2) Mrs. Manisha Swapnil Barve	16.08.2025	28.10.2025	Rs. 13,80,191.45/- (Rupees Thirteen Lakh Eighty Thousand One Hundred Ninety One and Four Five Paise Only) as of 02.02.2025	21.02.2026 09.00 AM to 05.30 PM	Rs. 10,00,069.00/- (Rupees Ten Lakh Eight Thousand Sixty Nine Paise Only)	Rs. 1,00,000.00/- (Rupees One Lakh Eight Hundred Six and Ninety Paise Only)	27.02.2026 11.00 AM to 2.00 PM	28.02.2026 before 05.00 PM Jana Small Finance Bank Ltd., 101 & 102, Ground Floor, Perfect Plaza (Prasadam), Plot No.97, Cement Road, Telegraph Colony, Pratap Nagar, Nagpur (MH)-440022.

Property Description Schedule: All the piece and parcel of land bearing Grampanchayat Mahajati Housa No.6774, total admeasuring 140.20 Sq.mtrs., together with Construction thereon, situated at Village Sukali within the limits of Grampanchayat Sukali, Talash & District Washin, Bounded by: East by: Property of Mr. Babanrao Bhishe, West by: Road, North by: Manohar Barve and South by: Shashikala Barve.

The properties are being held on "AS IS WHERE IS BASIS" and "AS IS WHAT IS BASIS" and the e-Auction will be conducted "On Line". All payments relating to purchase of above said property to be made in favour of Jana Small Finance Bank. The auction will be conducted through the Bank's approved service provider M/s. C-Quest at the web portal <https://bankauctio.in> & www.foreclosureindia.com. For more information and for details, help, procedure and online training on e-auction, prospective bidders may contact M/s. C-Quest; Contact Mr. Nitesh Pawar, Contact Number: 814200725. Email: niteshp@bankauctio.in, info@bankauctio.in. For further details on terms and conditions to take part in e-auction proceedings and any for any query relating to property please contact Jana Small Finance Bank officers Mr. Ranjan Jagtap (Mob. No.862951653). To the best of knowledge and information of the Authorized Officer, there are no encumbrances on the properties. However the intending bidders should make their own independent inquiries regarding the encumbrances, title of property put on prior to submitting their bid. No conditional bid will be accepted. This is also a notice to the above named Borrower(s)/Guarantor(s)/Mortgagor(s) about e-auction scheduled for the mortgaged properties. The Borrower/ Guarantor/ Mortgagor are hereby notified to pay the sum as mentioned above along with up to date interest and ancillary expenses before the date of auction, failing which the property will be sold and balance dues if any will be recovered with interest and cost.

Date: 10.02.2026, Place: Nagpur

Sd/- Authorized Officer, Jana Small Finance Bank Limited

The Indian Express
 JOURNALISM OF COURAGE

I choose substance over sensation.
 Inform your opinion with credible journalism.

The Indian Express.
 For the Indian Intelligent.

SHRIRAM Finance
SHRIRAM FINANCE LTD.,
 Registered Office: Sri Towers, Plot No.14A, South Phase, Industrial Estate, Guindy, Chennai - 600032.
 Administrative Office: Plot No 48, Neco Chambers, Sector-11, C.B.D Belapur, Navi Mumbai 400614.
 Authorized officer at - City Survey No-1036, Bearing Municipal House No. 3514/A/1153/U2, Ward No-20, Ashirwad Nagar, Mhalagji Nagar Square, Dist-Nagpur-440034.
 Branch Office: City Survey No-1036, Bearing Municipal House No. 3514/A/1153/U2, Ward No-20, Ashirwad Nagar, Mhalagji Nagar Square, Dist-Nagpur-440034.
 Website: www.shriramfinance.in

APPENDIX-IV-A [SEE PROVISION TO RULE 8(i)] SALE NOTICE FOR SALE OF IMMOVABLE PROPERTIES

E-Auction Sale Notice for Sale of Immovable Assets under the Securitization and Reconstruction of Financial Assets and Enforcement of Security Interest Act, 2002, read with provision to Rule 8 (i) of the Security Interest (Enforcement) Rules, 2002.

It is informed that "Shriram City Union Finance Ltd., has been amalgamated with "Shriram Transport Finance" as per the order of NCLT Chennai, subsequently the name of Shriram Transport Finance Ltd., was changed to "Shriram Finance Ltd.," with effect from 30-11-2022, vide certificate of incorporation pursuant to change of name dated 30-11-2022.

Notice is hereby given to the public in general and in particular to the Borrower(s) and Guarantor(s) that the below described immovable properties mortgaged/ charged to the Shriram Finance Limited (Earlier known as Shriram City Union Finance Limited), The Physical possession of which have been taken by the Authorized Officer of Shriram Finance Limited (Earlier known as Shriram City Union Finance Limited), will be sold on "As is where is", "As is what is" and "Whatever there is" basis in e-auction for recovery of the balance due to the "Shriram Finance Limited" from the Borrower(s) and Guarantor(s), as mentioned in the table. Details of Borrower(s) and Guarantor(s), amount due, Short Description of the immovable property and encumbrances known thereon, possession type, reserve price and earnest money deposit, Date and Time of Auction are also given as:

Name and Address of Borrowers/Co-Borrowers/ Guarantors/Mortgagors.	Date & Amount of 13(2) Demand Notice.	Description of Property	Reserve Price (Rs.) & Bid Increment	Earnest Money Deposit (EMD) Details	Date & Time of Auction	Contact Person and Inspection Date
1) M/s. Sai Krupa Builders Through its Proprietor of Mrs. Jyoti Nikhilesh Bele, Rio-Plot No. 131, Navdurga Society No-3, Manish Nagar, Beltarodi Road, Nagpur Maharashtra - 440035.	Loan Account No. NAGPUTF1803300004 Rs. 1,58,71,599/- (Rupees One Crore Fifty Nine Lakhs Seventy One Thousand Five Hundred Ninety Nine Only) on 15/12/2023 i.e. Demand Notice Dated. 30/12/2023	Immovable Property - Flat No-41, admeasuring 50,717 Sq. Mtrs., built up and 79,245 Sq. Mtrs. Super Built up area situated on the fourth floor of the building known and styled as "Siddhant Saksham Towers", constructed and having 6.66% of undivided share and interest in the land admeasuring 609.25 Sq. Mtrs. (as per sale deed) 507.306 Sq. Mtrs. (as per NIT Lease deed) bearing Plot No. 4 & 5 being the portion of entire land survey No. 61/1, bearing City Survey No. 1123, Sheet No. 197/22, bearing Property No. 195564+5401, of Mouza- Parsodi, Situated at- Bandhu Gruh Nirman Sahakar Sanstha, Ward No. 74, Lokhande Nagar, Shradhanand Peth, Nagpur, within the limits of Municipal Corporation Nagpur. Tah. & Dist. Nagpur.	Rs. 95,64,000/- (Rupees Ninety Five Lakh Sixty Four Thousand Only). Bid Increment: Rs. 50,000/- and in such multiples.	EMD amount to be deposited by way of Demand Draft (D.D) / Pay order in favor of Shriram Finance Ltd., payable at Nagpur.	Date: 18/03/2026 Time: 11.00 a.m. to 01.00 p.m.	Mr. Sahanand Charate 901191073 Mr. Mahesh Mohod 992220082
2) Mrs. Jyoti Nikhilesh Bele Aged about Major, Occ-Business, Rio-Plot No. 4 & 5, Flat No. 402, Fourth floor, Siddhant Saksham Tower, Gayatri Mandir, Lokhande Nagar Nagpur, Maharashtra - 440022.		Immovable Property II Flat No- 402, admeasuring 60,349 Sq. Mtrs., built up and 94,295 Sq. Mtrs. Super Built up area situated on the fourth floor of the building known and styled as "Siddhant Saksham Towers", constructed and having 7.932 % undivided share and interest in the land admeasuring 609.25 Sq. Mtrs. (as per sale deed) 507.306 Sq. Mtrs. (as per NIT Lease deed) bearing Plot No. 4 & 5 being the portion of entire land survey No. 61/1, bearing City Survey No. 1123, Sheet No. 197/22, bearing Property No. 195564+5402, of Mouza- Parsodi, Situated at- Bandhu Gruh Nirman Sahakar Sanstha, Ward No. 74, Lokhande Nagar, Shradhanand Peth, Nagpur, within the limits of Municipal Corporation Nagpur. Tah. & Dist. Nagpur.	Rs. 9,56,400/- (Rupees-Nine Lakh Fifty Six Thousand Four Hundred Only). Last Date for Submission of EMD: 17/03/2026 Time 10.00 a.m. to 05.00 p.m.		Property Inspection Date: 16/03/2026 Time 11.00 a.m. to 04.00 p.m.	
3) Mr. Nikhilesh Shivcharan Bele Aged about Major, Occ-Business, Rio-Plot No. 4&5, Flat No. 401, Fourth floor, Siddhant Saksham Tower, Lokhande Nagar Nagpur, Maharashtra - 440022.		Immovable Property Flat No. 67, Chandra Nagar, Parvati Nagar, Nagpur, Maharashtra - 440027.				
4) Mr. Sudhir Motilal Dhanvijay Aged about- Major, Occ-Business, Rio- Gali No-68 L, Near Budha Vihar, House No. 2208, Chandramani Nagar, Kukde Lay-out, Bhagwan Nagar, Nagpur, Maharashtra - 440027.		Boundaries of Land On the East-Plot No. 03, On the West- Kharsa Boundary of other layout, On the North- Kharsa Boundary of other layout, On the South- Road.				
5) Mr. Avinash Parashram Mate Aged about-Major, Occ-Business Plot No. 67, Chandra Nagar, Parvati Nagar, Nagpur, Maharashtra - 440027.						

For detailed terms and conditions of the sale, bid form, training & others may also visit website of Shriram Finance Limited (Earlier known as Shriram City Union Finance Limited) at <http://e.auctions.sam.in> Shriram Finance Ltd., (Earlier known as Shriram City Union Finance Ltd.)

STATUTORY 30 DAYS SALE NOTICE FOR SUBSEQUENT SALE UNDER RULE 8(i) AS PER AMENDED SARFAESI ACT, 2002.
 The mortgagors/borrowers are given a last chance to pay the total dues with further interest before auction, failing which secured assets will be sold as per above schedule.

The mortgagors/borrowers are Request to take back all movable items which are in the property.
 NB: Please note that the secured creditor is going to issue the sale notice to all the Borrowers / Guarantors/ Mortgagors by speed registered post. In case the same is not received by any of the parties, then this publication of sale notice may be treated as a substituted mode of service.

Place: Nagpur
 Date: 10/02/2026

Sd/-
 Authorized Officer
 Shriram Finance Ltd.,

